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The	   aim	   of	   this	   dissertation	   is	   to	   study	   how	   Corporate	   Social	   Responsibility	   (CSR)	   is	  
integrated	   in	   companies,	   with	   a	   special	   focus	   on	   the	   pharmaceutical	   industry.	   The	  
problem	   statement	   relies	   on	   understanding	   how	   has	   the	   tension	   between	   the	  
accessibility	   of	   essential	   medicines	   in	   developing	   countries	   and	   Intellectual	   Property	  
Rights	   (IPRs)	   influenced	   the	   CSR	   strategy	   of	   multinational	   companies	   in	   the	  
pharmaceutical	   industry	   over	   the	   last	   years.	   In	   order	   to	   act	   in	   accordance	   with	   this	  
objective,	   a	   teaching	   case	   was	   developed,	   based	   on	   GlaxoSmithKline	   (GSK),	   a	   British	  
multinational	   pharmaceutical	   that	   is	   the	   world’s	   second	   largest	   pharmaceutical	  
company	   and	   world	   leader	   in	   the	   provision	   of	   drugs	   to	   treat	   the	   three	   most	   critical	  
diseases	  in	  the	  developing	  world:	  HIV/AIDS,	  malaria	  and	  tuberculosis.	  GSK	  was	  the	  first	  
company	   from	   the	   industry	   to	   approach	   the	   access	   to	   medicines	   issue	   as	   a	   strategic	  
consideration,	  by	  incorporating	  it	  not	  only	  in	  its	  CSR	  strategy	  but	  also	  in	  the	  company’s	  
overall	   strategy.	   The	   challenge	   faced	   translates	   how	   CSR	   practices,	   when	   adopted	  
strategically,	  can	  simultaneously	  create	  economic	  and	  social	  value.	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Farmacêuticas	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O	   principal	   objectivo	   desta	   dissertação	   é	   estudar	   a	   forma	   como	   a	   Responsabilidade	  
Social	   é	   integrada	   nas	   empresas,	   com	   um	   foco	   especial	   na	   indústria	   farmacêutica.	   O	  
problema	   a	   investigar	   baseia-­‐se	   na	   compreensão	   da	   tensão	   entre	   o	   acesso	   a	  
medicamentos	   essencias	   em	   países	   em	   desenvolvimento	   e	   os	   direitos	   de	   propriedade	  
intellectual,	   e	   a	   sua	   influência	   na	   estratégia	   de	   Responsabilidade	   Social	   de	   empresas	  
multinacionais	   da	   indústria	   farmacêutica	   nos	   últimos	   anos.	   Com	   este	   objectivo,	   foi	  
desenvolvido	   um	   estudo	   de	   caso,	   baseado	   na	   GlaxoSmithKline	   (GSK),	   uma	   empresa	  
farmacêutica	  multinacional	   britânica,	   considerada	   a	   segunda	  maior	   do	  mundo	   e	   líder	  
mundial	  no	  fornecimento	  de	  medicamentos	  para	  tratar	  as	  três	  doenças	  mais	  críticas	  nos	  
países	   em	   desenvolvimento:	   HIV/SIDA,	   malária	   e	   tuberculose.	   A	   GSK	   foi	   a	   primeira	  
empresa	   da	   indústria	   a	   considerar	   o	   acesso	   a	   medicamentos	   essenciais	   um	   assunto	  
estratégico,	   tendo-­‐o	   incorporado	   não	   só	   na	   estratégia	   de	   Responsabilidade	   Social	   da	  
empresa	  mas	   também	  na	  estratégia	   global.	   	  O	  desafio	   enfrentado	  exemplifica	   como	  as	  
práticas	  de	  responsabilidade	  social,	  quando	  encaradas	  de	  uma	  forma	  estratégica,	  podem	  
simultaneamente	  criar	  valor	  económico	  e	  social.	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Preface	  
Addressing	  the	  way	  companies	  interact	  with	  society	  and	  contribute	  for	  welfare	  creation	  
through	   CSR	   became	   a	   research	   topic	   of	   my	   interest	   during	   my	   master	   exchange	  
semester	   in	   The	   Netherlands,	   where	   I	   studied	   subjects	   related	   to	   Global	   Business	   &	  
Stakeholder	  Management.	  Hence,	   I	   kept	   asking	  myself:	  Why	  do	   companies	   do	   so:	   is	   it	  
purely	  altruistic,	  or	  do	  they	  expect	  some	  sort	  of	  benefit?	  How	  do	  they	  align	  social	  issues	  
with	   current	   business	   practices?	   	   One	   of	   the	   issues	   we	   discussed	   once	   in	   class	   was	  
related	  with	  the	  pharmaceutical	   industry	  and	  the	  topic	  of	  access	  to	  medicines	  vs.	  IPRs.	  
As	   in	  my	   family	   there	   has	   always	   been	   a	   strong	   connection	   to	   the	   health	   sector,	   this	  
theme	   immediately	   captured	   my	   attention	   and	   created	   in	   me	   a	   desire	   to	   study	   it	   in	  
greater	  depth.	  	  
	  
Once	  I	  had	  the	  main	  topic	  in	  mind,	  all	  I	  needed	  was	  a	  successful	  story	  of	  a	  company	  from	  
the	   pharmaceutical	   industry	   through	   which	   I	   could	   demonstrate	   the	   importance	   of	  
strategic	  CSR	  in	  our	  times.	  Thanks	  	  to	  	  the	  	  suggestion	  	  of	  	  my	  	  advisor,	  Professor	  	  Susana	  	  
Frazão	  	   Pinheiro	  ,	   and	   my	   seminar	   colleagues,	   I	   had	   the	   honour	   to	   study	  
GlaxoSmithKline,	  a	  company	  that	  has	  always	  integrated	  social	  responsibility	  values	  and	  
that	   was	   the	   first	   from	   the	   industry	   to	   approach	   the	   access	   to	   medicines	   issue	   as	   a	  
strategic	  consideration.	  
	  
Bearing	  in	  mind	  that	  the	  final	  result	  would	  not	  be	  possible	  without	  the	  help	  and	  support	  
of	  several	  interveners,	  I	  may	  now	  address	  my	  gratitude	  to	  all	  the	  persons	  that	  made	  this	  
achievable.	  Firstly,	  I	  would	  like	  to	  thank	  my	  academic	  advisor,	  Professor	  Susana	  Frazão	  
Pinheiro,	   for	   the	   availability	   and	   support	   addressed	   to	   the	   dissertation.	   Secondly,	   I	  
would	   like	   to	  express	  my	  gratitude	   to	  GlaxoSmithKline,	   in	  particular	   to	  Dr.	  Maria	   João	  
Poole	  da	  Costa,	   and	   to	  Bayer	  Health	  Care,	   namely	  Dr.	  Andreas	  Fibig,	   and	  his	   staff,	  Mr.	  
Rong	  Yang,	  Ms.Ulrike	  Schröder	  and	  Mr.Ulrich-­‐Dietmar	  Madeja,	   for	  the	  accessibility	  and	  
openness	   throughout	   the	   research	  process.	  Moreover,	   I	  would	   like	   to	   thank	  my	   family	  
for	  all	  the	  support	  and	  patience,	  and	  for	  being	  a	  caring	  source	  of	  trust.	  Finally,	  I	  would	  
like	  to	  thank	  my	  friends	  for	  keeping	  me	  believing.	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Chapter	  1	  	  -­‐	  Introduction	  
Globalization,	  a	  process	  that	  can	  be	  defined	  as	  the	  intensification	  of	  cross-­‐border	  social	  
interactions,	   due	   to	   declining	   costs	   of	   connecting	   distant	   locations	   through	  
communication	  and	  the	  transfer	  of	  capital,	  goods,	  and	  people	  (Scherer	  &	  Palazzo	  2011),	  
facilitates	   instantaneous	   communication	   across	   borders,	   trade	   in	   goods	   and	   services,	  
and	   the	   availability	   of	   scientific	   information	   around	   the	   world	   (Balcius	   &	   Novotny	  
2011).	   This	   phenomenon,	   besides	   having	   increased	   opportunities	   and	   risks	   for	  
corporations	  and	  intensified	  competition,	  has	  led	  to	  a	  transnational	  interdependence	  of	  
economic,	   political	   and	   social	   actors.	   In	   particular,	   the	   debate	   about	   multinational	  
companies’	  role	  in	  the	  globalizing	  world	  has	  been	  intensified.	  
	  
In	  developing	  countries,	  despite	  substantial	  advancements	  regarding	  access	  to	  essential	  
medicines	   and	   treatments	   to	   fight	   HIV/AIDS,	   malaria	   and	   tuberculosis,	   access	   to	  
essential	   medicines	   is	   still	   not	   adequate.	   Mainly	   rooted	   in	   poverty,	   there	   are	   several	  
significant	  barriers	  to	  access.	  The	  WHO	  has	  identified	  four	  major	  factors	  affecting	  access	  
to	  medicines	  (WHO	  2010):	  
-­‐ Rational	  selection	  of	  medicines,	  for	  example	  via	  the	  WHO	  Model	  List	  of	  Essential	  
Medicines;	  
-­‐ Affordable	  Pricing;	  
-­‐ Sustainable	  Financing;	  
-­‐ Reliable	  medicines	  supply	  systems.	  
	  
In	   September	   2000,	   world	   leaders	   gathered	   at	   the	   Millennium	   Summit	   of	   the	   United	  
Nations	   (UN),	   at	   its	   headquarters	   in	   New	   York	   City,	   and	   adopted	   the	   UN	  Millennium	  
Declaration,	  with	  the	  purpose	  of	  committing	  their	  nations	  to	  a	  novel	  global	  partnership	  
to	   reduce	  extreme	  poverty	   in	   its	  many	  dimensions	  –	   income	  poverty,	   hunger,	   disease,	  
lack	   of	   appropriate	   shelter,	   and	   exclusion	   –	  while,	   at	   the	   same	   time,	   boosting	   gender	  
equality,	   education	   and	   environmental	   sustainability.	   Eight	   time-­‐bound	   targets	   were	  
established,	  named	  the	  Millennium	  Development	  Goals	  (MDGs),	  having	  as	  a	  deadline	  the	  
year	  of	  2015	  (Millennium	  Project	  2006).	  Three	  out	  of	  eight	  MDGs,	  eight	  out	  of	   sixteen	  
MDG	  targets	  and	  eighteen	  out	  of	  forty-­‐eight	  MDG	  are	  health-­‐related.	  Most	  health	  targets	  
cannot	   be	   achieved	   without	   medicines	   (annex	   1),	   and	   a	   target	   in	   particular	  
acknowledges	   the	   need	   to	   improve	   the	   availability	   of	   affordable	   medicines	   for	   the	  
world’s	   poor	   in	   cooperation	   with	   pharmaceutical	   companies	   (United	   Nations	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Millennium	   Goals	   2012).	   The	   level	   of	   seriousness	   of	   the	   issue	   has	   therefore	   achieved	  
global	  recognition.	  	  
	  
Focusing	  on	   the	  pharmaceutical	   industry,	   there	  does	  not	   seem	   to	  exist	  much	   criticism	  
about	  its	  functioning	  with	  regard	  to	  labor	  standards	  and	  environmental	  care.	  However,	  
the	  “access	  to	  medicines”	  performance	  does	  not	  follow	  the	  same	  path	  (Leisinger	  2005),	  
as	   the	   industry	  has	  enjoyed	  high	  profit	  margins	   for	  many	  years	  now	  and	   the	  public	   is	  
becoming	   aware	   of	   this	   fact.	   There	   is	   a	   perception	   that	   the	   industry	   has	   been	   greedy,	  
especially	  with	  regards	  to	  patent	  protection	  and	  resistance	  to	  generic	  challenges	  (Oxfam	  
2007).	   Patent	   protection	   gives	   exclusive	   rights	   to	   patent	   holder	   and	   the	   patented	  
product	   cannot	   be	   used	   (produced,	   marketed)	   without	   his	   consent	   during	   a	   certain	  
period	   of	   time.	   This	   leads	   to	   drug	   prices	   increase,	   especially	   in	   developing	   and	   least	  
developed	  countries,	  creating	  negative	  impacts	  on	  access	  for	  the	  poorest	  (Cohen-­‐Kohler	  
et	  al	  2008).	  	  
	  
As	  a	  consequence	  of	  the	  increased	  perception	  of	  the	  fact	  that	  there	  exist	  different	  social	  
and	   economic	   realities,	   particularly	   in	   developing	   and	   emerging	   countries,	   and	   of	   the	  
transnational	   interdependence	   of	   economic,	   political	   and	   social	   actors,	   people	   expect	  
more	  from	  a	  “responsible	  corporate	  citizen”	  nowadays	  than	  they	  did	  twenty	  years	  ago,	  
and	  so	  do	  governments,	  activists,	  and	  the	  media,	  which	  have	  become	  skillful	  at	  holding	  
companies	  accountable	   for	   the	  social	  consequences	  of	   their	  activities.	  Today	   there	   is	  a	  
growing	  wave	  of	  demands	  being	  placed	  upon	  the	  pharmaceutical	  industry	  to	  contribute	  
to	   improved	   access	   to	  medicines	   for	   poor	   patients	   in	   the	   developing	  world	   (Leisinger	  
2008).	  These	  challenges	  have	  captured	  my	  attention	  and	  interest,	  and	  motivated	  me	  to	  
develop	  the	  following	  research	  question:	  
	  
How	   has	   the	   tension	   between	   the	   Accessibility	   of	   Essential	   Medication	   in	   developing	  
countries	   and	   Intellectual	   Property	   Rights	   influenced	   the	   CSR	   strategy	   of	   multinational	  
companies	  in	  the	  pharmaceutical	  industry	  over	  the	  last	  years?	  
	  
	  
GlaxoSmithKline,	   a	   company	   that	   has	  been	   a	  pioneer	   in	   this	   area	   and	  has	   a	   long-­‐term	  
commitment	   with	   its	   access	   to	   medicines	   strategy,	   is	   used	   as	   a	   case	   study	   to	   better	  
understand	  what	  sustains	  the	  adoption	  of	  strategic	  CSR.	  The	  topic	  of	  CSR	  is	  among	  the	  
most	  heatedly	  debated	  globalization	  topics,	  and	  the	  urgency	  to	  give	  greater	  attention	  to	  
it	   comes	   not	   only	   from	   the	   realization	   that	   the	   criticism	   of	   business	   can	   reach	   higher	  
proportions	   than	  ever	  before	  due	   to	  globalization,	   affecting	  a	   corporation’s	   image	  and	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reputation,	  but	  also	   from	  the	  growing	  recognition	  that	  governments	   fail	   to	  solve	  many	  
social	  problems.	  What	  seems	  to	  have	  happened	  nowadays	  is	  that	  the	  debate	  about	  CSR	  
has	  switched	  from	  whether	  to	  make	  commitments	  to	  CSR	  to	  how	  (Smith	  2003).	  	  
	  
The	  topic	  investigated	  has	  been	  gaining	  importance,	  as	  corporations	  are	  more	  and	  more	  
challenged	   to	   meet	   social	   problems	   within	   changing	   environments.	   The	   approach	  
adopted	   included	   not	   only	   the	   analysis	   of	   the	   issue	   of	   access	   to	   medicines	   in	   South	  
Africa,	   but	   also	   its	   impact	   on	   the	   overall	   CSR	   strategy	   of	   GSK	   throughout	   the	   years,	  
which,	  as	  far	  as	  we	  know,	  has	  not	  been	  done	  before.	  The	  case	  developed	  can	  be	  used	  as	  a	  
learning	  and	  reflexion	  instrument.	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Chapter	  2	  –	  Methodology	  
Having	   in	   mind	   the	   research	   question	   presented	   in	   the	   introduction	   chapter,	   it	   was	  
important	  to	  collect	  the	  data.	  For	  the	  selection	  of	  appropriate	  research	  methods,	  advices	  
and	   limitations	  of	  previous	  papers	   in	   the	   field	  were	   reviewed.	  The	  dissertation	  uses	  a	  
cross-­‐sectional,	   retrospective,	   exploratory	   approach	   (Myers	   2009),	   based	   mainly	   on	  
secondary	  sources,	  namely	  academic	  articles,	  books,	  newspapers	  and	  a	  large	  variety	  of	  
websites,	  being	  the	  only	  primary	  source	  an	  interview	  made	  to	  the	  company.	  In	  general,	  
an	   interpretative	   research	   perspective	   is	   adopted,	   with	   an	   access	   to	   reality	   through	  
social	   construction,	   considering	   the	   context	   and	   people	   during	   the	   research	   (Myers	  
2009).	  
	  
Firstly,	   a	   literature	  review	   is	   conducted	  making	  use	  of	  academic	  databases	  and	  search	  
engines	   such	   as	   Google	   Scholar,	   Science	   Direct,	   EBSCO	   and	   Business	   Source	   Premier.	  
Relevant	   articles	   from	   journals	   such	   as	   the	   Harvard	   Business	   Review,	   California	  
Management	   Review,	   Journal	   of	   Business	   Ethics	   Education,	   Academy	   of	   Management	  
Review,	   Journal	   of	   Management	   Studies,	   Business	   and	   Society	   Review,	   and	   others	   were	  
used.	   Furthermore,	   a	   large	   variety	   of	   quality	   newspapers	   as	  well	   as	   publicly	   available	  
information	   about	   organizations	   were	   utilized.	   Secondly,	   a	   case	   study	   is	   conducted	  
based	   on	   information	   gathered	   from	   an	   interview,	   the	   company’s	  website	   and	   annual	  
reports,	  and	  information	  from	  internet	  sources	  namely	  articles	  and	  magazines	  in	  order	  
to	   add	   an	   independent	   view	   about	   the	   company.	   Regarding	   the	   qualitative	   data	  
collected,	  the	  interview	  with	  Dr.	  Maria	  João	  Poole	  da	  Costa,	  External	  Affairs	  Director	  of	  
GSK	   Portugal,	   was	   fundamental	   to	   gather	   detailed	   and	   reliable	   information	   about	   the	  
specific	  topic	  of	  GSK’s	  strategic	  CSR	  and	  access	  to	  medicines.	  An	  interview	  with	  the	  CEO	  
of	  Bayer	  Pharma	  AG,	  Dr.	  Andreas	  Fibig,	  and	  his	  staff,	  Mr.	  Rong	  Yang,	  Ms.Ulrike	  Schröder	  
and	   Mr.Ulrich-­‐Dietmar	   Madeja,	   was	   also	   conducted	   in	   order	   to	   promote	   a	   broader	  
discussion	  in	  the	  teaching	  notes	  section,	  allowing	  the	  teacher	  to	  focus	  not	  only	  on	  GSK	  
but	   also	   on	   another	   companies	   from	   the	   industry.	   It	   can	   also	   be	   useful	   for	   future	  
research	   in	   this	   field,	   as	   the	   company	   is	   also	   dealing	   with	   this	   issue.	   Finally,	   all	   the	  
information	   gathered	   was	   fundamental	   to	   elaborate	   the	   teaching	   notes	   chapter	   that	  
aims	  to	  analyze	  the	  exposed	  case	  by	  combining	  the	  result	  of	  a	  deep	  study	  about	  the	  case	  
with	  the	  research	  about	  this	  topic.	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Chapter	  3	  -­‐	  Literature	  Review	  
Corporate	  Social	  Responsibility	  
Defining	  CSR	  
Steven	  L.	  Wartick	  promoted	  the	  idea	  of	  moving	  from	  the	  study	  of	  business	  and	  society	  to	  
the	  study	  of	  business	  in	  societies,	  which	  can	  be	  seen	  as	  the	  defining	  paradigm	  for	  the	  field	  
of	  corporate	  citizenship	  (Wettstein	  2005).	  	  
	  
The	  topic	  of	  CSR	  is	  among	  the	  most	  hotly	  debated	  globalization	  topics.	  Nevertheless,	  to	  
make	   an	   informed	   judgment	   about	   the	   social	   responsibility	   of	   a	   company	   is	   a	   rather	  
difficult	  attempt,	  as	  there	  are	  a	  multitude	  of	  definitions	  of	  CSR	  (Leisinger	  2007),	  falling	  
into	   two	   general	   schools	   of	   thought:	   those	   that	   argue	   that	   business	   is	   obliged	   only	   to	  
maximize	   profits	   within	   the	   boundaries	   of	   the	   law	   and	   minimal	   ethical	   constraints	  
(Friedman	   1970;	   Levitt	   1958);	   and	   those	   that	   have	   suggested	   a	   broader	   range	   of	  
obligations	   towards	   society	   (Andrews	   1973;	   Carroll	   1979;	   Davis	   &	   Blomstrom	   1975;	  
Epstein	   1987;	   McGuire	   1963).	   An	   important	   attempt	   to	   bridge	   the	   gap	   between	  
economic	  and	  other	  expectations,	  and	  one	  of	  the	  most	   important	  conceptualizations	  of	  
CSR,	  was	  offered	  by	  Archie	  Carroll	  (1979),	  who	  proposed	  a	  definition	  of	  corporate	  social	  
responsibility	  where	  four	  levels	  of	  social	  responsibility	  are	  embraced:	  	  
-­‐ Economic	  –	  responsibility	  to	  produce	  goods	  and	  services	  that	  society	  wants	  and	  
to	  sell	  them	  at	  a	  profit;	  
-­‐ Legal	   –	   responsibility	   of	   fulfilling	   its	   economic	  mission	  with	   the	   framework	   of	  
legal	  requirements;	  
-­‐ Ethical	  –	  society	  expects	  businesses	  to	  carry	  out	  ethical	  obligations;	  
-­‐ Discretionary	  –	  society	  expects	  businesses	  to	  assume	  social	  roles	  over	  and	  above	  
those	  described	  above.	  
	  
First	   in	   importance,	   and	   on	   the	   bottom	   of	   the	   pyramid	   (annex	   2),	   are	   the	   economic	  
responsibilities,	   followed	   by	   the	   legal	   ones.	   Next	   on	   the	   pyramid	   come	   the	   ethical	  
responsibilities	  and	   lastly,	   and	  weighted	   lowest	   in	   importance,	   come	   the	  discretionary	  
(i.e.,	  voluntary)	  responsibilities,	  where	  philanthropy	  fits	  in;	  it	  is	  a	  voluntary	  activity	  that	  
is	   neither	   required	   nor	   expected.	   Therefore,	   it	   is	   possible	   to	   say	   that	   the	   social	  
responsibility	   of	   businesses	   embraces	   the	   economic,	   legal,	   ethical	   and	   discretionary	  
expectations	  that	  society	  has	  of	  organizations	  at	  a	  certain	  point	  of	  time.	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Approaches	  to	  CSR	  
Four	   approaches	   to	   CSR	   (inactive,	   reactive,	   active,	   and	   pro-­‐/interactive),	   which	   are	  
neither	  mutually	   exclusive	  nor	   represent	   “best”	   practice	  models,	   have	  developed	  over	  
the	  years,	  and	  are	  characterized	  by	  different	  procedural	  attributes,	  as	  shown	  in	  the	  table	  
below	  (van	  Tulder	  &	  van	  der	  Zwart	  2006):	  
	  
Table	  1.	  Approaches	  to	  CSR	  









Inside-­‐in	   Outside-­‐in	   Inside-­‐out	   In/outside-­‐in/out	  
‘Doing	  things	  right’	   ‘Don’t	  do	  things	  
wrong’	  
‘Doing	  the	  right	  
things’	  
‘Doing	  the	  right	  
things	  right’	  
‘Doing	  Well’	   ‘Doing	  well	  and	  
doing	  good’	  
‘Doing	  good’	   ‘Doing	  well	  by	  doing	  
good’	  
Source:	  van	  Tulder	  &	  van	  der	  Zwart	  2006	  
	  
The	  inactive	  approach	  brings	  back	  Friedman’s	  idea	  that	  the	  only	  “social	  responsibility	  of	  
business”	  is	  to	  “increase	  its	  profits”.	  According	  to	  his	  book,	  Capitalism	  and	  Freedom,	  “the	  
corporation	  is	  an	  instrument	  of	  the	  stockholders	  who	  own	  it.	  If	  the	  corporation	  makes	  a	  
contribution,	   it	   prevents	   the	   individual	   stockholder	   from	   himself	   deciding	   how	   he	  
should	  dispose	  of	  his	  funds”	  	  (Porter	  &	  Kramer	  2002).	  This	  is	  mainly	  an	  inward-­‐looking	  
(inside-­‐in)	   approach,	   aimed	   at	   efficiency	   and	   competitiveness,	   where	   the	   company	  
focuses	   on	   “doing	   things	   right”,	  where	  no	   fundamental	   or	   ethical	   questions	   are	   raised	  
about	  what	  they	  are	  doing.	  	  
	  
The	  reactive	  approach,	  which	  focuses	  also	  on	  efficiency,	  has	  a	  particular	  concern	  on	  “not	  
doing	  things	  wrong”.	  It	  is	  characterized	  as	  an	  outside-­‐in	  approach	  because	  the	  company	  
is	   socially	   responsive	   and	   responds	   to	   specific	   actions	   of	   external	   actors	   that	   could	  
damage	  its	  reputation.	  Corporate	  Philanthropy,	  when	  not	  applied	  strategically,	  can	  be	  a	  
practical	  manifestation	  of	  social	  responsiveness	  (Post,	  Lawrence	  &	  Weber	  2002),	  since	  
most	   corporate	   giving	   programs	   have	   no	   connection	  with	   the	   company’s	   strategy.	   Its	  
purpose	  is	  primarily	  to	  generate	  goodwill	  and	  positive	  publicity,	  and	  to	  boost	  employee	  
morale	  (Porter	  &	  Kramer	  2002).	  These	  two	  approaches	  to	  CSR,	  which	  are	  heavily	  wealth	  
oriented,	  focus	  mostly	  on	  output	  indicators	  such	  as	  short-­‐term	  returns	  and	  productivity.	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An	  active	  approach	  to	  CSR	  is	  inspired	  by	  ethical	  values	  and	  virtues	  on	  the	  basis	  of	  which	  
the	   company’s	   aims	   are	   elaborated	   (van	   Tulder	   &	   van	   der	   Zwart	   2006).	   This	   is	  
considered	   an	   inside-­‐out	   approach	   since	   the	   company	   is	   outward-­‐oriented,	   and	   is	  
focused	  on	  “doing	  the	  right	   things”.	  Nevertheless,	  ethical	  practices	  can	  result	   in	  “doing	  
the	  right	  things	  wrong”	  and	  competitive	  market-­‐oriented	  business	  practices	  can	  lead	  to	  
“doing	   the	  wrong	   things	   right”.	   Therefore,	   a	   new	   approach	   to	   CSR,	  where	   the	   tension	  
between	   ethics	   and	   efficiency	   is	   involved	   within	   a	   socially	   responsible	   manner,	   is	  
required:	  the	  pro-­/interactive	  	  approach.	  	  
	  
When	  adopting	  a	  proactive	  approach,	   a	   company	   takes	  on	  activities	   aimed	  at	   external	  
stakeholders	  right	  from	  the	  start	  of	  an	  issue	  life	  cycle.	  By	  doing	  so,	  it	  allows	  the	  company	  
to	  act	  quickly	  and	  to	  take	  advantage	  of	  the	  occasion	  by	  positioning	  itself	  at	  the	  forefront	  
of	  an	  issue	  that	  may	  become	  of	  major	  public	  interest.	  Therefore,	  there	  is	  an	  incentive	  to	  
act	  proactively	  so	  as	  to	  gain	  a	  first-­‐mover	  advantage	  (Falck	  &	  Heblich	  2007).	   	   It	   is	  also	  
interactive	   because	   there	   are	   “outside	   in”	   and	   “inside	   out”	   approaches,	   which	  
complement	   each	   other.	   Actors	   keep	   a	   constant	   dialogue	   with	   the	   purpose	   of	   talking	  
over	  norms	  to	  which	  everyone	  could	  agree,	  with	  the	  attempt	  of	  “doing	  the	  right	  things	  
right”.	  This	  approach,	  which	  adds	  a	  welfare	  orientation	  to	  the	  company’s	  intents,	  implies	  
a	   medium-­‐term	   profitability	   and	   longer-­‐term	   sustainability,	   and	   is	   linked	   to	   strategic	  
CSR,	  which	  will	  be	  developed	  further	  below.	  
Increasing	  Importance	  of	  CSR	  	  
As	  previously	  mentioned	  in	  the	  approaches	  to	  CSR,	  corporate	  attention	  to	  CSR	  can	  come	  
from	   a	   desire	   to	   do	   good	   (the	   “normative”	   case),	   an	   enlightened	   self-­‐interest	   (the	  
“business”	   case),	   or	   a	   mixture	   of	   these	   two	   motivations	   (Smith	   2003).	   According	   to	  
Porter	   &	   Kramer	   (2006),	   the	   four	   prevailing	   justifications/corporate	  motives	   for	   CSR	  
are:	  	  
-­‐ Moral	  obligation	  –	  duty	  to	  be	  good	  corporate	  citizens	  and	  to	  “do	  the	  right	  thing”;	  
-­‐ Sustainability	  –	  operate	  in	  ways	  that	  secure	  long-­‐term	  economic	  performance	  by	  
avoiding	  short-­‐term	  behaviours	  that	  are	  socially	  detrimental	  or	  environmentally	  
wasteful;	  
-­‐ License	  to	  operate	  –	  permission	  to	  do	  business	  from	  governments,	  communities	  
and	  other	  stakeholders;	  
-­‐ Reputation	   –	   CSR	   initiatives	   improve	   a	   company’s	   image,	   tones	   up	   its	   brand,	  
among	  others.	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Increased	  attention	  to	  CSR	  by	  corporations	  has	  not	  been	  fully	  voluntary	  (the	  “business”	  
case):	  a	  significant	  number	  of	  companies	  only	  realized	  its	  importance	  when	  surprised	  by	  
public	   responses	   to	   issues	   they	   had	   not	   previously	   considered	   part	   of	   their	   business	  
responsibilities	   (Porter	  &	  Kramer	  2006).	  The	  urgency	   to	  give	  greater	  attention	   to	  CSR	  
comes	   not	   only	   from	   the	   realization	   that	   the	   criticism	   of	   business	   can	   reach	   higher	  
proportions	   than	   ever	   before	   due	   to	   globalization,	   as	   firms	   now	   operate	   in	   countries	  
with	  significantly	  different	  and	  generally	  much	  lower	  standards	  of	   living	  than	  the	  ones	  
of	   their	  domestic	  base,	  but	  also	   from	  the	  growing	  recognition	   that	  governments	   fail	   to	  
solve	  many	  social	  problems.	  	  
	  
Zooming	  into	  the	  pharmaceutical	  industry	  in	  particular,	  while	  there	  does	  not	  seem	  
to	   exist	   much	   criticism	   about	   its	   functioning	   with	   regard	   to	   labor	   standards	   and	  
environmental	   care,	   the	   “access	   to	  medicines”	   performance	   does	   not	   follow	   the	   same	  
path	   (Leisinger	   2005),	   as	   these	   corporations	   found	   out,	   for	   example,	   that	   they	   were	  
expected	  to	  respond	  to	  the	  AIDS	  pandemic	  in	  Africa	  even	  though	  it	  didn’t	  belong	  to	  their	  
primary	  product	   lines	  and	  markets.	  People	  expect	  more	  from	  a	  “responsible	  corporate	  
citizen”	  nowadays	  than	  they	  did	  twenty	  years	  ago,	  as	  a	  consequence	  of	  different	  social	  
and	  economic	  realities,	  particularly	  in	  developing	  and	  emerging	  countries.	  	  
	  
In	   addition,	   governments,	   activists,	   and	   the	   media	   have	   become	   skillful	   at	   holding	  
companies	   to	   account	   for	   the	   social	   consequences	   of	   their	   activities:	   government	  
regulation,	   more	   and	   more,	   requires	   social	   responsibility	   reporting;	   activists	   have	  
become	  much	  more	   aggressive	   and	   effective	   in	   conveying	   public	   pressure	   to	   bear	   on	  
corporations;	  and	  more	  extensive	  media	  reach,	  conjugated	  with	  advances	  in	  information	  
technology,	  has	   led	  to	  a	   fast	  and	  widespread	  exposure	  of	  corporate	  abuses	   in	  even	  the	  
most	  distant	  places	   in	   the	  world	   (Porter	  &	  Kramer	  2006).	  Furthermore,	  organizations	  
that	  rank	  companies	  on	  the	  performance	  of	  their	  CSR,	  which	  attract	  significant	  publicity,	  
have	  emerged,	  such	  as	  the	  Access	  to	  Medicine	  Index.	  This	  Index	  uses	  a	  framework	  that	  
evaluates	   the	  activities	  of	  a	  company	   in	  seven	   technical	  areas,	   considered	   to	  be	  key	   to	  
enhance	   access	   to	  medicine	   in	   developing	   countries,	   including:	   R&D	   activities,	   pricing	  
schemes,	  and	  patents	  &	   licensing	  policies;	  and	  across	   four	   important	  aspects	  of	  action,	  
or	  strategic	  pillars:	  commitments,	  transparency,	  performance	  and	  innovation	  (annex	  5).	  
It	   aims	   to	   stimulate	   pharmaceutical	   companies	   to	   increase	   their	   efforts	   to	   improve	  
access	  to	  medicine	  worldwide,	  by	  publicly	  providing	  a	  picture	  of	  the	  companies’	  access	  
to	   medicine	   activities.	   Today,	   the	   Access	   to	   Medicine	   Foundation	   receives	   financial	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support	   from	   donors	   including	   the	   Bill	   &	  Melinda	   Gates	   Foundation,	   and	   the	   UK	   and	  
Dutch	  Governments	  (Access	  to	  Medicine	  Index	  2013).	  	  
	  
As	  referred	  before,	  a	  vital	  consideration	  for	  many	  firms	  is	  reputational	  risk	  in	  consumer,	  
capital	   and	   labor	   markets.	   Today,	   large	   international	   enterprises	   –	   including	   the	  
research-­‐based	   pharmaceutical	   industry	   –	   have	   a	   significant	   reputational	   problem	   to	  
solve:	   a	   study	   conducted	   between	   1999	   and	   20011,	   where	   people	   were	   asked	   which	  
institutions	  they	  trusted	  to	  work	  in	  the	  best	  interest	  of	  society,	  ranked	  NGOs	  in	  the	  first	  
place,	  followed	  by	  religious	  organizations.	  Multinational	  companies	  were	  in	  the	  seventh	  
position,	  behind	  governments,	  unions	  and	  the	  media	  (Leisinger	  2005).	  The	  self-­‐image	  of	  
pharmaceutical	   companies	   in	   particular	   goes	   wrong	   with	   its	   public	   image	   since	   a	  
considerable	  number	  of	  people	  of	  industrial	  societies,	  when	  considering	  the	  protection	  
of	   the	   “common	  good”,	   conceive	  multinational	   corporations	   as	  more	   likely	   part	   of	   the	  
problem	  than	  part	  of	  the	  solution	  (Enderle	  &	  Peters	  1998).	  These	  pressures	  can	  become	  
a	  potentially	  large	  financial	  risk	  for	  pharmaceutical	  companies	  since	  the	  research-­‐based	  
pharmaceutical	   industry	   is	   highly	   regulated	   and	   hence	   ultimately	   depend	   on	   the	  
goodwill	  of	  political	  institutions.	  	  
	  
The	  most	  powerful	  argument	  Friedman	  had	  against	  CSR	  was	  that	  it	  was	  not	  in	  the	  best	  
interest	   of	   shareholders.	   However,	   Martin	   (2002)	   has	   noticed	   that	   firms	   frequently	  
engage	   in	   CSR	   “precisely	   because	   it	   enhances	   shareholder	   value”	   and	   some	   CSR	  
activities	   “create	   goodwill	   among	   consumers	   in	   excess	   of	   their	   price	   tag”.	   It	   has	   been	  
found	   that,	   from	   the	   nearly	   100	   studies	   done	   over	   the	   last	   30	   years	   about	   the	  
relationship	   between	   corporate	   social	   performance	   (CSP)	   and	   corporate	   financial	  
performance	  (CFP),	  most	  found	  a	  positive	  relationship	  between	  CSP	  and	  CFP	  (Margolis	  
&	  Walsh	  2001).	  
	  
Nowadays,	   most	   large	   corporations	   embrace	   a	   commitment	   to	   CSR	   and,	   in	   some	  
situations,	   their	   initiatives	   go	   afar	   from	   corporate	   philanthropy	   and	   corporate	  
communications	   that	   endeavor	   to	   defend	   the	   firm’s	   societal	   impacts	   (SustainAbility	  
2002).	   What	   seems	   to	   have	   happened	   nowadays	   is	   that	   the	   debate	   about	   CSR	   has	  
switched	  from	  whether	  to	  make	  commitments	  to	  CSR	  to	  how	  (Smith	  2003).	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  No	  more	  recent	  studies	  that	  included	  the	  public	  image	  of	  the	  pharmaceutical	  industry	  were	  
found.	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Strategic	  CSR	  
Successful	  corporations	  need	  a	  healthy	  society	  and,	  at	  the	  same	  time,	  a	  healthy	  society	  
needs	   successful	   corporations.	  The	   interdependence	  of	   these	   two	  spheres	   comes	   from	  
the	  fact	  that	  education,	  health	  care	  and	  equal	  opportunity	  are	  essential	  to	  a	  productive	  
workforce	   but,	   at	   the	   same	   time,	   no	   social	   program	   can	   compete	   with	   the	   business	  
sector	  in	  regards	  of	  creating	  the	  jobs,	  wealth,	  and	  innovation	  that	  ameliorate	  standards	  
of	  living	  and	  social	  conditions	  (Porter	  &	  Kramer	  2006).	  
	  
Today,	   the	   most	   common	   approach	   to	   CSR	   is	   neither	   strategic	   nor	   operational,	   but	  
decorative,	  with	  published	  annual	  CSR	  reports	  that	   lack	  a	  coherent	  framework	  for	  CSR	  
activities	  and	  that	  describe	  philanthropic	  initiatives	  in	  terms	  of	  numbers:	  dollars	  spent,	  
hours	   spent,	   among	   others;	   and	  most	   of	   the	   relations	   between	   corporations	   and	   civil	  
society	   are	   characterized	   by	   friction	   rather	   than	   cooperation.	   In	   order	   to	   develop	   the	  
right	   CSR	   strategy,	   understanding	   a	   company’s	   mission,	   values	   and	   core	   business	  
activities	   is	   fundamental	   to	   comprehend	   what	   differentiates	   it	   from	   the	   other	  
organizations,	   in	   order	   to	   choose	   a	   unique	   position	   (Smith	   2003).	   Porter	   &	   Kramer	  
(2006)	   state	   that	   if	   corporations,	   applying	   the	   frameworks	   that	   guide	   their	   core	  
business	  choices,	  analyzed	  their	  prospects	  for	  social	  responsibility,	  they	  would	  come	  to	  
the	  conclusion	  that	  CSR	  can	  be	  much	  more	  than	  a	  cost,	  a	  constraint	  or	  a	  charitable	  need	  
–	   it	   can	   be	   a	   source	   of	   opportunity,	   innovation,	   and	   competitive	   advantage,	   since	   the	  
business	   puts	   in	   practice	   resources,	   expertise	   and	   insights	   to	   activities	   that	   benefit	  
society.	   These	   two	   spheres	   are	   interdependent,	   which	   connotes	   that	   decisions	   made	  
from	  both	   sides	  must	   follow	   the	   principle	   of	   shared	   value:	   choices	  must	   benefit	   both.	  
Furthermore,	  effective	  CSR	  is	  normally	  a	  long-­‐term	  position:	  since	  it	  is	  an	  investment	  in	  
the	  company’s	  future,	  it	  requires	  planning,	  supervision	  and	  evaluation	  on	  a	  regular	  basis	  
(Falck	   &	  Heblich	   2007).	   	   In	   order	   to	   do	   so,	   corporations	   have	   to	   incorporate	   a	   social	  
perspective	  into	  the	  core	  model	  that	  is	  exercised	  to	  comprehend	  competition	  and	  guide	  
its	  business	  strategy	  in	  key	  five	  steps	  (Porter	  &	  Kramer	  2006):	  
	  
1. Identify	  the	  points	  of	  intersection	  between	  society	  and	  the	  corporation	  
	  
2. Choose	   which	   social	   issues	   to	   address	   –	   Falck	   &	   Heblich	   (2007)	   developed	   a	  
framework	  to	  decide	  which	  stakeholders	  should	  be	  considered	  and	  how	  much	  is	  at	  
stake,	  which	  is	  presented	  in	  the	  figure	  below:	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Figure	  1.	  Falck	  &	  Heblich	  (2007)	  Framework	  
	  
	  
The	  decision	  making	  process	   is	  started	  by	  a	  social	  trend,	  which	  has	  to	  be	  evaluated	  by	  
the	   company	   (the	   first	   step	   of	   strategic	   planning)	   in	   order	   to	   see	   if	   it	   can	   achieve	  
significant	   dimensions.	   If	   it	   is	   a	   claim	   of	   a	   marginal	   group	   and	   is	   liable	   to	   disappear	  
quickly,	  then	  no	  action	  should	  be	  taken.	  On	  the	  other	  hand,	  if	  it	  can	  become	  a	  claim	  with	  
significant	   dimensions	   and	   if	   stakeholders	   are	   involved	   or	   interested,	   the	   claim	   can	  
affect	   the	   company.	   Nevertheless,	   the	   decision	   of	   stepping	   in	   should	   be	   based	   on	   an	  
evaluation	  of	  the	  opportunities	  and	  threats	  implied,	  what	  is	  at	  stake.	  Once	  again,	  Falck	  &	  
Heblich	   (2007)	   propose	   a	   cost-­‐benefit	   analysis	   to	   calculate	   the	   expected	   net	   present	  
value	  of	  the	  future	  cash	  flow:	  	  
	  
Trend	   Stakeholder	   Stake	   Strategy	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The	   priority	   given	   to	   the	   trend	   should	   be	   based	   on	   the	   interested	   stakeholder’s	  
importance,	  which	  is	  based	  on	  its	  impact	  on	  the	  company’s	  cash	  flow.	  Key	  stakeholders,	  
such	  as	  the	  most	  important	  suppliers	  and	  key	  clients,	  have	  a	  direct	  link	  to	  the	  company	  
and	  can	  influence	  the	  current	  and	  expected	  cash	  flow,	  with	  low	  volatility.	  As	  so,	  they	  are	  
the	  ones	   to	  be	   considered	  when	  calculating	   the	  expected	  net	  present	  value	  of	   the	  CSR	  
action.	  Emerging	  stakeholders,	   like	  suppliers	  with	  some	   influence,	  NGOs	  working	  with	  
sensitive	  issues	  and	  politicians	  that	  can	  change	  the	  institutional	  framework,	  do	  not	  have	  
a	  linear	  linkage	  with	  the	  corporation’s	  cash	  flow	  and	  do	  not	  influence	  the	  expected	  net	  
present	   value.	   However,	   emerging	   stakeholders	   can	   become	   key	   stakeholders	   all	   of	   a	  
sudden.	  The	  volatility	  of	  their	  expected	  cash	  flow	  is	  high	  and	  therefore	  this	  group	  must	  
be	  monitored	  regularly.	  Lastly	  come	  the	  minor	  stakeholders,	  that	  are	  not	  able	  to	  create	  a	  
damaging	  impact	  and	  that	  don’t	  need	  much	  attention.	  The	  expected	  cash	  flow	  volatility	  
is	  low.	  	  
	  
The	  decision	  criteria	   is	   the	  expected	  net	  present	  value	  of	   the	  social	   investment,	  which	  
can	   be	   an	   individual	   or	   a	   collective	   commitment.	   A	   strategic	   action	   of	   an	   individual	  
commitment	   type	   should	   be	   chosen	   if	   the	   claim	   can	   be	   done	   with	   no	   risk	   of	  
opportunistic	   behaviour	   (exclusive	   take),	   which	   grants	   the	   company	   a	   first-­‐mover	  
advantage,	  which	   can	   improve	   reputation	  among	   customers	   and	   thus	   increase	  market	  
share.	   On	   the	   other	   hand,	   if	   the	   issue	   is	   a	   collective	   problem,	   a	   single	   enterprise’s	  
individual	  commitment	  is	  a	  risky	  investment,	  which	  will	  only	  be	  successful	  if	  it	  does	  not	  
take	   the	   company	   to	   a	   competitive	   disadvantage	   in	   the	   long	   run.	   There	   should	   be	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required	  a	  collective	  commitment,	  and	  a	  structural	  action:	  as	  all	  competitors	  are	  linked	  
to	  this	  code,	  there	  are	  no	  distortions	  of	  competition.	  	  
	  
3. Create	   a	   corporate	   social	   agenda	   –	   To	   look	   beyond	   expectations,	   to	   create	  
opportunities	   to	   reach	   social	   and	   economic	   benefits	   at	   the	   same	   time.	   It	   must	   be	  
responsive	  to	  stakeholders	  but,	  most	  important,	  it	  must	  focus	  on	  strategic	  CSR,	  since	  
is	   through	   it	   that	   the	   most	   significant	   social	   impact	   and	   business	   benefits	   are	  
achieved.	   Initiatives	   consider	   clear	   and	   measurable	   goals	   and	   track	   results	   over	  
time.	  Also,	  the	  company	  should	  define	  how	  much	  is	  enough,	  by	  defining,	  in	  the	  case	  of	  
a	  pharmaceutical	  company	  for	  example,	  how	  far	  should	  the	  company	  assist	  in	  drug	  
distribution	  and	  administration,	  how	  much	  should	  be	  developed	  in	  R&D	  to	  develop	  
medicines	  for	  tropical	  diseases,	  among	  others.	  
	  
4. Integrate	  inside-­out	  and	  outside-­in	  practices	  –	  It	  is	  all	  about	  the	  pro-­‐/interactive	  
approach	  to	  CSR	  developed	  above.	  Here	  is	  where	  the	  opportunities	  to	  create	  shared	  
value	  truly	  exist.	  
	  
5. Create	   a	   social	   dimension	   to	   the	   value	   proposition	   –	   The	   most	   strategic	   CSR	  
happens	  when	   companies	   incorporate	   a	   social	   dimension	   to	   its	   value	   proposition,	  
making	  social	  impact	  part	  of	  the	  overall	  strategy.	  
	  
Corporate	  Philanthropy,	  which,	  as	  previously	  mentioned,	  belongs	  to	  the	  fourth	   level	  of	  
social	  responsibility	  embraced	  by	  companies	  according	  to	  Carroll	  (1979),	  can	  also	  give	  
companies	   a	   powerful	   competitive	   edge,	   if	   developed	   strategically	   (Smith	   1994).	  
According	  to	  Porter	  &	  Kramer	  (2002),	  the	  majority	  of	  corporate	  contribution	  programs	  
are	   diffuse	   and	   unfocused,	   reflecting	   the	   personal	   beliefs	   and	   values	   of	   executives	   or	  
employees.	  “Strategic	  philanthropy”	  generally	  means	  that	  there	  is	  a	  connection	  between	  
the	   charitable	   contribution	   and	   the	   company’s	   business,	   a	   context-­‐focused	   approach:	  
corporations	  can	  use	  their	  charitable	  efforts	  to	  meliorate	  their	  competitive	  context.	  Still,	  
in	  order	  to	  do	  so,	  corporations	  need	  to	  rethink	  both	  where	  they	  focus	  their	  philanthropy	  
and	   how	   they	   go	   about	   their	   giving.	   The	   more	   a	   social	   improvement	   relates	   to	   a	  
company’s	  business,	  the	  more	  it	  leads	  to	  economic	  benefits	  as	  well,	  meaning	  that,	  in	  the	  
long	  run,	  social	  and	  economic	  goals	  are	  integrally	  connected.	  	  
	  
Strategic	   CSR	   is	   a	   very	   selective	   process,	   since	   companies	   are	   called	   to	   address	   an	  
enormous	  amount	  of	  social	  issues,	  but	  only	  a	  few	  symbolize	  real	  opportunities	  to	  make	  a	  
difference	   to	   society	   or	   to	   achieve	   competitive	   advantage.	   Nevertheless,	   as	   nowadays	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competitiveness	   has	   increased	   and	   more	   and	   more	   companies	   meet	   the	   quality	  
requirements	   of	   the	  market,	   consumers	  will	   differentiate	   companies	   through	   the	  way	  
the	  company	  behind	  the	  product	  or	  service	  stands	  for	  in	  society	  and	  CSR	  might	  make	  a	  
significant	   difference	   at	   the	   margin	   of	   many	   firms	   (Smith	   2003).	   The	   pharmaceutical	  
industry	  is	  not	  an	  exception,	  and	  the	  way	  companies	  have	  been	  dealing	  with	  the	  issue	  of	  
access	   to	   medicines	   vs.	   IPRs,	   which	   will	   be	   further	   developed	   below,	   can	   make	   a	  
significant	  difference	  at	  the	  margin	  of	  many	  of	  them.	  	  
The	  Issue	  –	  Access	  to	  Medicines	  vs.	  Intellectual	  Property	  Rights	  
Access	  to	  Medicines	  	  
According	   to	   the	  WHO,	   “essential	   medicines	   are	   those	   that	   satisfy	   the	   priority	   health	  
care	   needs	   of	   the	   population”	   and	   “are	   intended	   to	   be	   available	  within	   the	   context	   of	  
functioning	  health	  systems	  at	  all	  times	  in	  adequate	  amounts,	  in	  the	  appropriate	  dosage	  
forms,	  with	  assured	  quality,	  and	  at	  a	  price	  the	  individual	  and	  the	  community	  can	  afford”	  
(WHO	   2013).	   The	   human	   right	   to	   essential	   medicines	   is	   a	   derivative	   right	   from	   the	  
rights	   to	  health	  and	   life	   (Marks	  2009)	   since,	   as	   reported	  by	   the	  WHO,	  more	   than	  10.5	  
million	   lives	   would	   be	   saved	   by	   2015	   if	   the	   access	   to	   existing	   interventions,	   namely	  
medicines	   for	   infectious	   diseases,	   maternal	   and	   child	   health,	   and	   noncommunicable	  
diseases	  increased	  (WHO	  2004).	  In	  particular,	  and	  as	  a	  result	  of	  the	  AIDS	  pandemic,	  the	  
critical	  need	   for	   treatment	  of	  HIV	   conduced	   to	   the	   recognition	   that	   access	   to	   essential	  
medicines,	  including	  antiretroviral	  treatments	  (ARTs),	  is	  a	  human	  right.	  	  
	  
Recent	   data2	   exhibits	   that	   essential	   medicines	   remain	   unaffordable	   and	   insufficiently	  
accessible	   to	   the	   poor	   (annex	   3)	   (MDG	   Gap	   Task	   Force	   Report	   2012).	   Regarding	   the	  
median	  prices	  for	  drugs	  (annex	  4),	   in	  developing	  countries	  prices	  were	  on	  average	  2.6	  
times	  higher	  in	  the	  public	  sector	  in	  comparison	  to	  International	  Reference	  Prices	  (IRPs),	  
a	   project	   internationally	   accepted,	   created	   with	   the	   purpose	   of	   developing	   a	  
standardized	   survey	   methodology	   for	   measuring	   medicine	   prices,	   availability,	  
affordability	  and	  price	  components	  (WHO	  2013). However,	  because	  the	  public	  sector	  in	  
developing	  countries	  frequently	  fails	  to	  provide	  affordable	  medicines	  reliably,	  often	  the	  
poorest	   people	   are	   the	   ones	   paying	   the	   highest	   out-­‐of-­‐pocket	   expenses	   for	  medicines	  
(Leach,	  Munderi	  &	  Paluzzi	  2005).	  In	  these	  countries,	   in	  the	  private	  sector,	  patients	  pay	  
five	  times	  more	  than	  the	  IRPs	  (MDG	  Gap	  Task	  Force	  Report	  2012).	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
2During	   the	   period	   2007-­‐2011,	   medicine	   price	   and	   availability	   data	   from	   17	   national	   and	  
subnational	   surveys	   in	   low-­‐	   and	   middle-­‐income	   countries	   were	   undertaken	   using	   the	   World	  
Health	  Organization/Health	  Action	  International	  (WHO/HAI)	  methodology.	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Intellectual	  Property	  Rights	  
Intellectual	   property	   rights	   refer	   to	   the	   general	   term	   for	   the	   assignment	   of	   property	  
rights	   through	   patents,	   copyrights,	   and	   trademarks.	   The	   aim	   of	   IPRs	   is	   to	   restrict	  
imitation	   and	   duplication:	   ideas	   and	   knowledge	   are	   an	   increasingly	   important	   part	   of	  
trade	  and	  most	  of	  the	  value	  of	  new	  medicines	  and	  other	  high	  technology	  products	  lies	  in	  
the	  amount	  of	  invention,	  innovation,	  research,	  design	  and	  testing	  involved	  (WTO	  2012).	  	  
	  
The	  extent	  of	  protection	  and	  enforcement	  of	  IPRs	  varied	  widely	  around	  the	  world	  and,	  
as	   intellectual	   property	   became	  more	   important	   in	   trade,	   these	   differences	   became	   a	  
source	   of	   tension	   in	   international	   economic	   relations	   (Maskus	   &	   Fink	   2005).	   New	  
internationally-­‐agreed	  trade	  rules	  for	  intellectual	  property	  rights	  were	  seen	  as	  a	  way	  to	  
introduce	   more	   order	   and	   predictability,	   and	   for	   disputes	   to	   be	   settled	   more	  
systematically	   (WTO	  2012).	  The	  Trade-­‐Related	  Aspects	  of	   Intellectual	  Property	  Rights	  
(TRIPS),	   negotiated	   in	   the	   1986-­‐94	   Uruguay	   Round,	   introduced	   intellectual	   property	  
rules	   into	   the	   multilateral	   trading	   system	   for	   the	   first	   time	   (WTO	   2012).	   Prior	   to	   its	  
establishment,	   pharmaceutical	   products	   had	   no	   patent	   protection	   in	  many	   developing	  
countries.	  	  
	  
In	  terms	  of	  effect	  on	  price	  and	  access	  to	  medicines,	  it	  has	  been	  proven	  that	  TRIPS	  has	  a	  
negative	   consequence	   for	   drug	   costs,	   given	   the	   impact	   of	   generic	   competition	   on	  
reducing	  price	  (Cohen-­‐Kohler	  et	  al	  2008).	  Several	  scholars	  (Kremer	  &	  Glennerster	  2004;	  
Lanjouw	  2005)	  argue	  that	  the	  harmonization	  of	  patents	  is	  both	  unworkable	  and	  costly	  
for	  several	  reasons,	  particularly	  for	  poor	  countries.	  They	  include	  extreme	  differences	  in	  
the	  technological	  effort	  of	  countries,	  differences	  in	  the	  costs	  and	  benefits	  of	  IP	  protection	  
and	   the	   difficulty	   in	   enforcement.	  Widespread	   criticism	  of	   patent	   rights	   continues	   not	  
only	   in	   the	   developing	   world	   but	   also	   from	   many	   scholars	   in	   the	   developed	   world	  
(Stiglitz	  2003).	  The	  issue	  of	  whether	  the	  current	  patent	  system	  serves	  as	  a	  guide	  to	  an	  
effective	  public	  policy	  is	  by	  no	  means	  settled	  (Lanjouw	  2005).	  	  
	  
Regarding	  literature	  on	  the	  topic	  of	  protection	  of	  IPR,	  it	  has	  been	  proven	  that	  stronger	  
protection	   of	   IPR	   increases	   bilateral	   trade	   flows	   of	   manufactured	   non-­‐fuel	   imports	  
(Braga	   and	   Fink	   1999).	   In	   regards	   of	   the	   relationship	   between	   IPR	   protection	   and	  
innovation,	   research	   showcased	   a	   positive	   relationship	   (Chen	   &	   Puttitanun	   2005).	  
However,	   the	   evidence	   is	   stronger	   for	   developed	   countries	   than	   for	   developing	  
countries.	   In	   addition,	   it	   has	   been	   concluded	   that	   different	   patent-­‐policy	   instruments	  
have	   different	   effects	   on	  R&D	   and	   growth.	   The	   optimal	   level	   of	   IPR	  protection	   should	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trade-­‐off	  the	  social	  benefits	  of	  enhanced	  innovation	  against	  the	  social	  costs	  of	  multiple	  
distortions	   and	   income	   inequality.	   Theory	   on	   the	   topic	   of	   IPR	   protection	   is	   context	  
bound	  and,	  regarding	  the	  measurement	  of	  the	  issue,	  different	  positions	  have	  been	  taken	  
which	  has	  lead	  to	  contradictory	  results	  (Chu	  2009).	  
Pharmaceutical	  Industry	  in	  transition	  on	  the	  topic	  of	  R&D	  
The	   pharmaceutical	   industry	   is,	   at	   this	   time,	   facing	   a	   period	   of	   very	   significant	  
transformation,	   as	   the	   key	   for	   success	   no	   longer	   relies	   exclusively	   upon	   new	   drugs	  
development	   (Blanchard	   &	   Spada	   2003).	   Participants	   in	   the	   industry	   face	   vivid	  
competition	   not	   only	   because	   margins	   for	   non-­‐patented	   products	   decreased	   (generic	  
competition	  has	  already	  dented	  Big	  Pharmaceuticals’	  revenues)	  but	  also	  due	  to	  the	  fact	  
that	   the	   number	   of	   generic	   drug	   manufacturers	   increased,	   which,	   opposite	   to	   the	  
research-­‐oriented	   pharmaceutical	   companies,	   spend	  minimum	   resources	   on	   R&D	   and	  
therefore	  sell	  the	  products	  at	  a	  significantly	  lower	  price.	  Pressure	  comes	  also	  from	  new	  
players,	  especially	  in	  Asia	  (Drost	  &	  Hain	  2010).	  	  
	  
Zooming	  into	  structural	  changes,	  the	  majority	  of	  pharmaceutical	  companies	  bring	  forth	  
high	  returns,	  benefiting	  from	  excess	  cash	  for	  further	  rapid	  growth	  (Pharma	  2020	  2011).	  
In	  order	   to	  diversify	   the	  drugs	  portfolio	  and	  gain	  stability	   in	   the	   long	  term,	  and	  taking	  
into	   account	   that	   the	   development	   process	   of	   drugs	   takes	   many	   years	   and	   requires	  
significant	  investments	  that	  don’t	  have	  a	  clear	  and	  guaranteed	  outcome,	  top	  companies	  
in	   the	   industry	   have	   been	   active	   participants	   of	   mergers	   and	   acquisitions,	   strategic	  
alliances	   with	   their	   competitors,	   collaborations	   with	   generic	   companies,	   new	   joint	  
ventures	  and	  spin-­‐offs	  of	  non-­‐core	  businesses	  (Davidson	  &	  Greblov	  2005).	  
Increasing	  Role	  of	  Governments	  in	  Developing	  Countries	  
In	   many	   developing	   economies,	   governments	   are	   looking	   for	   means	   to	   amplify	   their	  
limited	  health	   service	   coverage.	   Some	   of	   the	   main	   objectives	   acknowledge	   extending	  
basic	  coverage,	  widening	  the	  health	  services	  covered	  and	  reducing	  the	  amount	  of	  health	  
costs	  supported	  directly	  by	  patients	  (MacKenzie	  &	  Webb	  2011).	  A	  reliable	  public	  health	  
care	  is	  critical	  for	  sustainable	  development	  (Connolly	  &	  Goguen	  2012)	  as	  it	  is	  reported	  
that	   emerging	   nations	   expanding	   their	   public-­‐sector	   health	   care	   are	   associated	   with	  
stronger	  economic	  growth	  as	  well	   as	  quality	  of	   life	   improvement	   (MacKenzie	  &	  Webb	  
2011).	   A	   study	   based	   on	   databases	   of	   WHO	   and	   IMF	   shows	   that	   in	   all	   developing	  
countries	  there	  was	  a	  substantial	   increase	  in	  public	  financing	  for	  health	  from	  domestic	  
sources—nearly	  100%	  (IMF	  120%,	  WHO	  88%)	  from	  1995	  to	  2006,	  having	  this	  overall	  
increase	  been	  the	  product	  of	  rising	  GDP,	  slight	  decreases	   in	  the	  share	  of	  GDP	  spent	  by	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government,	   and	   increases	   in	   the	   share	   of	   government	   spending	   on	   health	   (Lu	   et	   al.	  
2010).	  	  
	  
Nevertheless,	   the	   primary	   duty	   bearers	   –	   states	   and	   their	   authorities	   –	   cannot	   be	  
dismissed	   from	   their	   responsibilities.	   According	   to	   Leisinger	   (2009),	   those	   in	   power	  
must	   insure	   that	   policy	   reforms,	   good	   governance	   and	   institution-­‐building	   efforts	  
resolve	   the	   systemic	   deficits	   and	   political	   inadequacies	   that	   are	   so	   frequently	   at	   the	  
origin	   of	   health	   problems,	   since	   economic	   growth	   is	   a	   necessary,	   but	   not	   sufficient,	  
precondition	   for	   sustainable	   development.	   	   Although	   international	   assistance	   and	  
cooperation	   for	   health	   development	  must	   be	   part	   of	   the	   required	   effort	   to	   realize	   the	  
right	   to	   health,	   no	   external	   resource	   can	   replace	   necessary	   internal	   reforms	   to	   satisfy	  
the	  basic	  health	  needs.	  	  Support	  from	  external	  sources	  –	  development	  agencies,	  NGOs,	  or	  
corporations	  –	  will	  only	  be	  as	  effective	  as	  the	  domestic	  political	  and	  social	  constraints	  on	  
health	  systems	  will	  allow.	  	  
Increasing	  Role	  of	  Civil	  Society	  
Civil	   Society	   organizations,	   most	   commonly	   known	   as	   NGOs,	   have	   the	   function	   of	  
organizing	  society.	  Operating	  at	  two	  interfaces,	  between	  the	  state	  and	  civil	  society	  and	  
between	  the	  market	  and	  civil	  society,	  NGOs	  act	  in	  advocacy	  roles	  for	  particular	  concerns,	  
such	  as	  the	  access	  to	  medicines	  issue	  (Balcius	  &	  Novotny	  2011).	  The	  first	  interface	  is	  the	  
most	   traditional,	   as	   many	   NGOs	   appeal	   to	   government	   to	   obtain	   extra	   funding	   for	  
projects	  they	  carry	  out	  on	  behalf	  of	  civil	  society.	   It	  has	  been	  revealed	  that	  poor	  people	  
often	   consider	   the	   role	   of	   governments	   ineffective	   and	   even	   harmful,	   due	   mainly	   to	  
corruption,	  whereas	  NGOs	  score	  highly	  for	  responsiveness	  and	  trust	  (Leisinger	  2009).	  It	  
is,	   however,	   the	   second	   interface	   in	   particular,	   market	   vs.	   civil	   society,	   that	   is	  
undergoing	   change.	   Since	   the	   beginning	   of	   the	   1990s,	   NGOs	   have	   been	   claiming	  
companies	   to	   account	   for	   their	   social	   responsibilities.	   Elkington	   &	   Fennell	   (1998)	  
classify	  four	  different	  types	  of	  positions	  NGOs	  can	  adopt	  in	  order	  to	  do	  so:	  (1)	  sharks,	  (2)	  
orcas,	  (3)	  sea	  lions	  and	  (4)	  dolphins.	  Sharks	  and	  orcas	  are	  inclined	  towards	  polarization	  
and	  confrontation,	  and	  act	  more	  (sharks)	  or	   less	  (orcas)	   instinctively	  and	  strategically.	  
On	   the	  other	  hand,	   sea	   lions	  and	  dolphins	  are	  more	   inclined	   towards	  cooperation.	  Sea	  
lions	  will	  accept	  sponsorship	  from	  companies,	  while	  dolphins	  recognize	  that	  companies	  
can	  create	   important	  preconditions	   to	  achieve	  desired	  change	  but	  prefer	   to	  keep	   their	  
independence.	  Many	  NGOs	  start	  out	  as	  sharks,	  but	  the	  categories	  of	  orcas	  and	  dolphins	  
have	   gained	   importance	   and	   appeal	   throughout	   the	   years.	   Sweeping	   claims	   about	  
globalization	   and	   empowerment	   are	   made	   not	   only	   with	   regard	   to	   the	   role	   of	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multinational	  companies,	  but	  also	  with	  regard	  to	  international	  civil	  society.	  Employment	  
in	   the	   non-­‐profit	   sector	   is	   an	   estimation	   of	   the	   direct	   economic	   significance	   of	   civil	  
society	  (Hupe	  &	  Meijs	  2000),	  having	  increased	  since	  the	  late	  1980s.	  	  
Pharmaceutical	  Industry	  Position	  
The	  industry	  considers	  that	  “the	  case	  is	  nothing	  to	  do	  with	  blocking	  access	  to	  medicines	  
or	   price	   fixing.	   It’s	   about	   patents.	   Patents	   do	   not	   block	   medicines,	   they	   stimulate	  
research	  and	  development”	  (The	  Guardian	  2001).	  According	  to	  GSK	  (2011),	  “developing	  
an	  innovative	  pharmaceutical	  product	  or	  vaccine	  is	  costly	  and	  risky,	  since	  it	  requires	  the	  
discovery	  of	  active	  substances	  suitable	  for	  treating	  or	  preventing	  the	  medical	  condition;	  
developing	  them	  into	  formulations	  suitable	  for	  administration	  to	  patients;	  and	  satisfying	  
the	   regulatory	   authorities	   in	   all	   countries	   where	   the	   product	   is	   to	   be	   sold	   that	   the	  
product	  is	  safe	  and	  effective”.	  1.2	  billion	  dollars	  is	  the	  estimated	  average	  cost	  of	  taking	  a	  
new	  pharmaceutical	  product	  to	  the	  market,	  including	  the	  cost	  of	  failure,	  and	  only	  one	  in	  
three	  drugs	  brought	  to	  market	  is	  profitable.	  In	  addition,	  companies	  would	  not	  incur	  the	  
risk	  and	  cost	  of	  innovative	  R&D	  if	  they	  knew	  that,	  in	  a	  short	  period	  of	  time,	  a	  competitor	  
who	  had	  the	  competitive	  advantage	  of	  not	  having	  to	  incur	  in	  developing	  costs	  provided	  
a	   cheaper	   copy.	   Therefore,	   a	   period	   of	   time	   free	   from	   competition	   is	   required	   to	  
stimulate	   innovation	   and	   reward	   for	   innovation.	   Without	   proper	   IPR	   protection,	   the	  
medicines	  that	  are	  needed	  in	  the	  developing	  world	  are	  less	  likely	  to	  be	  developed.	  
New	  approaches	  to	  Global	  Health	  Governance:	  The	  Evolution	  to	  Partnerships	  
Globalization	  has	  come	  together	  with	  a	  reassessment	  of	  the	  strengths	  and	  weaknesses	  of	  
public/governmental,	  private/commercial,	  and	  civil	  society	   institutions	  in	  dealing	  with	  
the	  world	  problems.	  In	  the	  health	  area	  in	  particular,	   it	  has	  been	  realized	  that	  the	  most	  
difficult	  to	  manage	  problems	  need	  new	  ways	  of	  working	  together,	   in	  addition	  to	  better	  
coordination	  of	   traditional	  roles,	  so	   to	  reach	  a	  combination	  of	   the	  strengths,	  resources	  
and	   expertise	   of	   the	   different	   sectors	   (Widdus	   2001).	   	   When	   very	   different	   types	   of	  
organizations	   work	   together,	   the	   probability	   of	   clashes	   of	   goals,	   objectives,	   values,	  
cultures,	   strategies,	   management	   styles,	   and	   operating	   approaches	   is	   high.	  
Notwithstanding,	  some	  of	  these	  relationships	  may	  prosper	  and	  turn	  into	  close,	  mutually	  
beneficial	   long-­‐term	   partnerships	   designed	   to	   achieve	   strategic	   goals	   for	   the	   parts	  
involved	  (Berger,	  Cunningham	  &	  Drumwright	  2004).	  	  
	  
A	   collaborative	   partnership	   is	   an	   alliance	   between	   people	   and	   organizations	   from	  
multiple	  sectors,	  with	  the	  aim	  of	  achieving	  a	  common	  purpose.	   In	  the	  case	  of	  health	   in	  
particular,	   the	   goal	   is	   to	   improve	   conditions	   and	   well	   being	   of	   society.	   According	   to	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published	   literature,	   collaborative	   partnerships	   have	   become	   an	   increasingly	   popular,	  
and	  several	  assumptions	  underlie	  this	  strategy	  (Roussos	  &	  Fawcett	  2000):	  
1. The	  goal	  cannot	  be	  reached	  by	  an	  individual	  or	  group	  working	  alone;	  
2. Participants	   should	   include	   a	   variety	   of	   individuals	   or	   groups	  who	   represent	   the	  
concern	  and/or	  geographic	  area;	  
3. Shared	  interests	  generate	  consensus	  among	  the	  prospective	  partners	  possible.	  	  
	  
This	   consensus	   spawned	   the	   need	   for	   new	   collaborative	   thinking,	   economic	  
commitment	   and	   governance	   structure.	   Examples	   of	   public-­‐private	   partnerships	   that	  
have	  already	  been	  successful	  are	  numerous	  and	  research	  and	  development	  partnerships	  
are	  also	  emerging.	  The	  breaking	  down	  of	  geopolitical	  barriers	  has	  matched	  the	  breaking	  
down	  of	   traditional	   public	   vs.	   private	   lines	   in	  health	  development	   (Balcius	  &	  Novotny	  
2011).	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Chapter	  4	  -­‐	  Case	  Study	  
Issue	  Overview	  
In	  developing	  countries,	  despite	  substantial	  advancements	  regarding	  access	  to	  essential	  
medicines	   and	   treatments	   to	   fight	   HIV/AIDS,	   malaria	   and	   tuberculosis,	   access	   to	  
essential	   medicines	   is	   still	   not	   adequate.	   There	   exist	   several	   significant	   barriers	   to	  
access	  in	  the	  developing	  world.	  Rooted	  in	  poverty,	  the	  problem	  results	  in	  an	  inability	  to	  
pay	   for	   even	   the	   cheapest	   medicines,	   including	   generics.	   Limited	   availability	   in	   the	  
public	   sector	   is	   frequently	   due	   to	   a	   lack	   of	   resources,	   under-­‐budgeting,	   inaccurate	  
demand	  forecasting	  or	  inefficient	  procurement	  and	  distribution3.	  Although	  the	  average	  
availability	  is	  higher	  in	  private	  facilities,	  in	  most	  low	  and	  lower-­‐middle	  income	  countries	  
the	  poor	  rely	  on	  the	  public	  sector	  to	  obtain	  medicines,	  as	  they	  are	  free	  of	  charge	  or	  the	  
prices	  are	  significantly	  lower	  than	  in	  the	  private	  sector,	  the	  latter	  offering	  mostly	  higher-­‐
priced	  originator	  brands	  because	  of	  higher	  manufacturers’	  prices,	  taxes	  and	  tariffs,	  and	  
high	  mark-­‐ups	  in	  the	  supply-­‐chain.	  Zooming	  into	  HIV	  in	  particular,	  in	  2010,	  worldwide,	  
about	  34	  million	  people	  were	  living	  with	  HIV.	  The	  number	  of	  people	  dying	  from	  AIDS-­‐
related	   causes	   in	   2010	  was	   1.8	  million,	   0.4	  million	   less	   than	   in	   20054.	   This	   decline	   is	  
explained,	  besides	  greater	  efforts	  at	  prevention	  and	  behavioural	  change,	  by	  a	  significant	  
increase	  in	  access	  to	  ARV	  treatment:	  18%	  in	  low	  and	  middle-­‐income	  countries	  in	  2010,	  
being	  most	  of	  the	  facilities	  from	  the	  public	  sector5.	  	  
	  
Intellectual	   property	   rights	   refer	   to	   the	   general	   term	   for	   the	   assignment	   of	   property	  
rights	   through	   patents,	   copyrights,	   and	   trademarks.	   These	   property	   rights	   allow	   the	  
holder	  to	  exercise	  a	  monopoly	  on	  the	  use	  of	  the	  item	  for	  a	  specified	  period6.	  In	  both	  rich	  
and	  poor	  countries,	  nowhere	  is	  the	  tension	  between	  markets	  and	  public	  policy	  greater	  
than	  in	  the	  global	  pharmaceutical	  industry7.	  At	  the	  centre	  of	  this	  tension	  is	  the	  need	  to	  
preserve	  incentives	  for	  innovation	  by	  granting	  patents,	  while	  at	  the	  same	  time	  keeping	  
the	  price	  of	  prescription	  drugs	  affordable	   in	  order	  to	   improve	  the	  access	  to	  medicines.	  
The	  WTO’s	  Agreement	  on	  Trade-­‐Related	  Aspects	  of	  Intellectual	  Property	  Rights	  (TRIPS),	  
negotiated	   in	   the	  1986-­‐94	  Uruguay	  Round,	   introduced	   intellectual	   property	   rules	   into	  
the	   multilateral	   trading	   system	   for	   the	   first	   time8.	   The	   TRIPS	   agreement	   required	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  MDG	  Gap	  Task	  Force	  Report	  2011	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  UNAIDS	  2011	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  Gap	  Task	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  2012	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member	  nations	  to	  be	  in	  compliance	  with	  the	  minimum	  standards	  for	  IPR	  protection	  by	  
the	  year	  2006,	  which	  include,	  amongst	  others,	  that	  patents	  be	  given	  for	  a	  minimum	  of	  20	  
years;	   that	   patents	   may	   be	   given	   both	   for	   products	   and	   processes;	   and	   that	  
pharmaceutical	   test	   data	   can	   be	   protected	   against	   “unfair	   commercial	   use”.	  
Furthermore,	  in	  November	  2001,	  the	  members	  of	  the	  WTO	  agreed	  the	  Doha	  Declaration	  
on	   TRIPS	   and	   Public	  Health,	  which	   reaffirms	   IPRs	   but	   as	  well	   the	   ability	   to	   introduce	  
flexibilities	   in	   regulations	   –	   exempted	   the	   least	   developed	   countries	   from	   complying	  
with	  TRIPS	  until	  the	  1st	  of	  January	  2016.	  Society	  benefits	  in	  the	  long	  term	  as	  intellectual	  
property	  protection	  encourages	  creation	  and	  invention	  but	  governments	  are	  allowed	  to	  
reduce	   any	   short-­‐term	   costs	   through	   various	   exceptions,	   for	   example	   to	   tackle	   public	  
health	  problems	  by	  means	  of	  granting	  a	  compulsory	  license,	  in	  light	  of	  their	  own	  social	  
and	  economic	  conditions.	  
	  
	  However,	  TRIPS	  implementation	  transition	  of	   less	  developed	  nations	  has	  resulted	  in	  a	  
lower	   IPR	   enforcement	   level	   than	   envisioned.	   This	   has	   created	   friction	   between	  
developing	  nations	  with	  lower	  IPR	  enforcement	  and	  the	  developed	  nations	  with	  higher	  
IPR	   enforcement.	   As	   a	   consequence,	   many	   nations	   have	   entered	   into	   Free	   Trade	  
Agreements	   to	   further	   raise	   the	   IPR	   enforcement	   standards	   that	   TRIPS	   laid	   out9,	   and	  
that	  was	  how	  TRIPS	  PLUS	  emerged,	  which	  implements	  even	  tougher	  or	  more	  restrictive	  
conditions	   in	   their	  patent	   laws	  than	  are	  required	  by	  the	  TRIPS.	   International	   law	  does	  
not	  oblige	  countries	   to	  engage	   in	   these	  conditions	  but	   some,	   such	  as	  Brazil	  and	  China,	  
have	  no	  other	  option	  but	  to	  adopt	  it,	  since	  they	  have	  trade	  agreements	  with	  the	  United	  
States	  and	  the	  European	  Union10.	  
	  
In	  developing	  economies	  and	  emerging	  economies	  in	  particular,	  governments	  have	  been	  
adopting	   health	   strategies	   that	   are	  motivated	   by	   the	   belief	   that	   the	   right	   to	   health	   is	  
more	   important	   than	   economic	   gain,	   such	   as	   health-­‐related	   research	   and	   product	  
innovation11.	  The	  engagement	  in	  this	  point	  of	  view	  means	  governments	  adopt	  a	  position	  
where	  intellectual	  property	  rights	  should	  not	  hinder	  broad	  access	  to	  life-­‐medicines:	  all	  
countries	   should	   have	   access	   to	   information	   and	   innovative	   technologies	   to	   fight	  
diseases	   and	   improve	   health,	   meaning	   it	   is	   not	   appropriate	   to	   use	   law	   enforcement	  
mechanisms	  to	  protect	  patents	  at	  the	  expense	  of	  people’s	  access	  to	  necessary	  medicines.	  
Some	  governments,	  such	  as	  Brazil,	  Thailand,	  India	  and	  South	  Africa	  have	  done	  precisely	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  2008	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that.	  In	   addition	   to	   this,	   activists	   have	   become	  much	  more	   aggressive	   and	   effective	   in	  
conveying	  public	  pressure	   to	  bear	  on	  corporations	  and,	  with	   the	  help	  of	   the	  extensive	  
media	   reach,	   it	   has	   become	   easier	   to	   achieve	   a	   fast	   and	   widespread	   exposure	   of	  
corporate	  abuses12.	  In	  the	  South	  African	  issue	  about	  pricing	  policies	  for	  patented	  drugs	  
for	  example,	  which	  will	  be	  further	  developed	  below,	  the	  NGO	  Oxfam	  took	  advantage	  of	  
the	   media	   attention	   and	   launched	   a	   campaign	   accusing	   the	   Western	   pharmaceutical	  
Industry	  of	   carrying	  an	   “undeclared	  drug	  war”	  on	  poor	  countries.	  These	  organizations	  
play	   a	   critical	   role	   in	   raising	   awareness,	   as	   they	  may	   act	   as	   watchdogs,	   denunciating	  
interventions	  of	  various	  actors.	  	  
	  
The	  pharmaceutical	   industry	  considers	  misleading	  and	  counter-­‐productive	   to	   focus	  on	  
patents	   in	   the	   access	   to	   medicines	   debate	   and	   considers	   that	   the	   current	   intellectual	  
property	   regime	   does	   not	   constitute	   a	   serious	   barrier,	   believing	   that	   strict	   levels	   of	  
intellectual	  property	  protection	  are	  indispensable	  to	  stimulate	  R&D,	  even	  in	  developing	  
countries13.	  There	  are	  many	  significant	  barriers	   to	  access	   in	   the	  developing	  world,	  but	  
the	  industry	  believes	  the	  most	  obvious	  and	  fundamental	  barriers	  to	  access	  to	  health	  care	  
and	  medicines	   are	   poverty,	  which	   results	   in	   an	   inability	   to	   pay	   for	   even	   the	   cheapest	  
medicines,	  and	  the	  under-­‐investment	  on	  health	  infrastructures14.	  These	  issues	  can	  only	  
be	   addressed	   if	   not	   only	   the	   pharmaceutical	   industry	   but	   all	   sectors	   of	   global	   society	  
share	  responsibilities	  and	  work	  together.	  In	  addition	  to	  this	  challenge,	  the	  “blockbuster”	  
model,	  which	  enabled	  companies	  to	  build	  their	  businesses	  around	  a	  selected	  number	  of	  
products,	  is	  no	  longer	  sustainable15,	  as	  the	  industry	  is	  facing	  reduced	  patent	  protection.	  
Drug	  development	  is	  facing	  rising	  costs	  due	  to	  a	  decrease	  in	  R&D	  productivity	  and	  socio-­‐
political	  pressure	  for	  more	  affordable	  and	  available	  life	  saving	  drugs	  has	  increased.	  
	  
About	  GSK	  
Established	   in	   2000	   by	   the	   merger	   of	   Glaxo	   Wellcome	   and	   SmithKline	   Beecham,	  
GlaxoSmithKline	   is	  a	  British	  multinational	  pharmaceutical,	  headquartered	   in	  Brentford	  
(UK)	   and	   with	   operations	   based	   in	   the	   US.	   This	   merger	   created	   the	   world’s	   second	  
largest	  pharmaceutical	  company	  and	  the	  world’s	  leader	  in	  the	  provision	  of	  drugs	  to	  treat	  
the	   three	   most	   critical	   diseases	   in	   the	   developing	   world:	   HIV/AIDS,	   malaria	   and	  
tuberculosis.	   As	   a	   science-­‐led	   global	   healthcare	   company,	   the	   three	   primary	   areas	   of	  
business	   are	   pharmaceuticals	   (68%	   of	   the	   group),	   vaccines	   (13%	   of	   the	   group)	   and	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  2006	  
13	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  2008	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consumer	  healthcare	   (19%	  of	   the	   group)16.	  GSK’s	  mission	   is	   to	   improve	   the	  quality	   of	  
human	   life	   by	   enabling	   people	   to	   do	   more,	   feel	   better	   and	   live	   longer.	   With	   99,488	  
employees,	   the	   geographic	   presence	   of	   the	   company	   covers	  more	   than	   100	   countries	  
(exhibit	   1).	   The	   shape	   of	   the	   business	   is	   shifting	   to	   capitalize	   on	   markets	   with	   high-­‐
growth	   potential,	   including	   those	   in	   Asia	   Pacific,	   Latin	   America	   and	   Japan.	   Territories	  
outside	  the	  USA	  and	  Europe	  now	  account	  for	  40%	  of	  the	  total	  sales	  of	  GSK.	  The	  company	  
has	   a	   significant	   global	   manufacturing	   and	   R&D	   presence,	   with	   a	   network	   of	   87	  
manufacturing	  sites	  and	  large	  R&D	  centers	  in	  the	  UK,	  USA,	  Spain,	  Belgium	  and	  China.	  
The	  South	  African	  Case	  
Nelson	   Mandela,	   elected	   president	   of	   South	   Africa	   in	   1994	   after	   the	   first	   democratic	  
elections,	  had	  as	  a	  priority	  on	  the	  agenda	  of	   the	  post-­‐apartheid	  government	  to	  make	  a	  
health	  care	  reform,	  since	  many	  South	  Africans	  did	  not	  have	  access	  to	  health	  care	  at	  all.	  
The	  most	  significant	  deficiencies	  were	  the	  lack	  of	  equity	  in	  access	  to	  essential	  drugs,	  the	  
comparatively	   high	   prices	   for	   pharmaceuticals	   in	   the	   private	   sector	   and,	   due	   to	   poor	  
security	  in	  the	  public	  sector,	  losses	  of	  drugs17.	  
	  
In	   1997,	  Nelson	  Mandela	   signed	   the	  Medicines	   and	  Related	   Substance	  Act	   (exhibit	   2),	  
which	   allowed	   parallel	   importing	   and	   compulsory	   licensing	   in	   order	   to	   harness	   the	  
HIV/AIDS	   pandemic	   in	   South	   Africa	   (exhibit	   3),	   which	   further	   contributed	   to	   the	  
magnitude	   of	   the	   health	   care	   problem.	   Parallel	   importing,	   such	   as	   importing	  
pharmaceuticals	   from	  any	  origin,	  admitting	  generic	  manufacturers	  careless	  of	  whether	  
the	  patent	  holders	  approved,	  would	  generate	  less	  expensive,	  generic	  drugs	  available	  to	  
the	   citizens;	   and	   compulsory	   licensing	  would	   give	   the	   government	   the	   opportunity	   to	  
grant	  local	  companies	  authorization	  to	  fabricate	  generics	  even	  when	  valid	  patents	  were	  
held	   by	   foreign	   companies18.	   Between	   1998	   and	   2001	   the	   issue	   grew	   and	   gained	  
significant	  international	  dimension.	  
	  
GSK	  and	  other	  large	  pharmaceutical	  companies	  considered	  both	  provisions	  in	  the	  Act	  an	  
assault	   on	   its	   IPR	   and,	   together	   with	   38	   pharmaceutical	   manufacturers	   and	   with	   the	  
support	  of	  the	  USA	  and	  the	  European	  Commission,	  the	  company	  filed	  a	  lawsuit	  against	  
the	   government	   of	   South	   Africa	   “alleging	   that	   the	   Medicines	   and	   Related	   Substances	  
Control	   Act	   violated	   TRIPS	   and	   the	   South	   African	   constitution”19.	   The	   South	   African	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government	  ended	  up	  not	  implementing	  Mandela’s	  law	  at	  that	  time	  because	  the	  country	  
aimed	  to	  become	  a	  significant	  global	  trading	  partner.	  	  
	  
Nevertheless,	   international	  opinion	  changed	  early	   in	  2001,	  when	  the	  case	  was	  brought	  
to	   court,	   as	   society	   demanded	   cheaper	   drugs.	   The	   pressure	   on	   GSK	   increased	  mainly	  
because	  CIPLA,	  the	  largest	  Indian	  drug	  manufacturer,	  had	  proposed	  to	  sell	  aggressively	  
discounted	   copies	   of	   GSK’s	   ARV	   medicines	   to	   NGOs.	   India,	   considered	   a	   developing	  
country	  by	  the	  WTO,	  has	  an	  extension	  on	  putting	  TRIPS	  agreements	  and	  obligation	  into	  
effect,	  meaning	  its	  producers,	  such	  as	  CIPLA,	  have	  the	  permission	  to	  produce	  copies	  of	  
drugs	  that	  are	  patented	  and	  developed	  elsewhere.	  CIPLA	  gave	  for	  free	  its	  drug	  Duovir	  (a	  
copy	  of	  GSK’s	  Combivir)	  to	  Médecins	  Sans	  Frontières	  and	  also	  at	  a	  very	  low	  price	  to	  the	  
South	  African	  government.	  	  
	  
Media	   attention	   on	   pricing	   policies	   for	   patented	   drugs	   increased	   at	   that	   time	   and	   the	  
NGO	  Oxfam	  took	  advantage	  of	  that	  by	  launching	  a	  campaign	  entitled	  “Cut	  the	  Cost”.	  This	  
campaign,	   which	   accused	   the	   Western	   pharmaceutical	   industry	   of	   waging	   an	  
“undeclared	  drug	  war”	  on	  poor	  countries,	   required	  the	   industry	   to	  drop	  their	   lawsuits	  
against	   countries	   that	  produce	   cheaper	  generic	  medicines	   and	  had	  as	   a	   specific	   target	  
the	  world	  market	   leader	  GSK20.	   In	  February	  2001,	  GSK	  decided	   to	  cut	   the	  price	  of	  HIV	  
medicine	  and	   in	  May,	  as	   there	  was	  no	  support	   from	  home	  governments	  and	   increased	  
international	   public	   pressure,	   pharmaceutical	   companies	   ended	   up	   agreeing	   on	  
dropping	  the	  case	  against	  the	  South	  African	  government.	  	  
	  
Meanwhile	   in	   the	   US,	   critical	   stakeholders	   also	   manifested	   themselves,	   demanding	   a	  
change	  in	  the	  corporate	  behaviour	  of	  GSK.	  The	  South	  African	  court	  case	  and	  the	  access	  
problem	  demonstrated	  an	  industry	  in	  crisis	  concerning	  the	  scope	  and	  meaning	  of	  social	  
responsibility.	  	  
Lawsuit	  dropped,	  Issue	  resolved?	  
Despite	   the	  withdrawal	   from	  the	  South	  African	  case,	   the	  pharmaceutical	   industry	  kept	  
being	   publicly	   criticized.	   At	   GSK’s	   annual	   meeting	   in	   May	   2001,	   activists	   dressed	   in	  
white	  laboratory	  coats	  distributed	  leaflets	  challenging	  GSK	  to	  demonstrate	  leadership	  in	  
the	   industry	   and	   take	   relevant	   steps	   to	   develop	   more	   affordable	   medicines	   for	   the	  
poorest,	   by	   donating	   a	   percentage	   of	   drug	   revenues	   to	   the	   UN	   Secretary	   General’s	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“global	  health	  fund”21.	  In	  addition,	  Oxfam	  warned	  pharmaceutical	  companies	  they	  would	  
lose	   public	   support	   if	   they	   kept	   in	   their	   patent	   strategies	   and,	   once	   again,	   challenged	  
GSK	   to	   take	   the	   lead	   in	   this	   transformation	   process.	   In	   June,	   GSK	   extended	   the	  
distribution	   of	   cheaper	   ARVs	   and	   announced	   a	   two-­‐year	   price	   freeze	   on	   HIV/AIDS	  
medicines.	   The	   table	   below	   summarizes	   GSK’s	   societal	   interface	   management	  
challenges.	  
	  
Table	  2.	  GSK	  Societal	  Interface	  Management	  Challenges	  
Source:	  Adapted	  from	  van	  Tulder	  &	  van	  der	  Zwart	  2005	  
GSK	  Indicators	  of	  Reputational	  Damage	  
In	  order	  to	  analyze	  the	  impact	  that	  patent	  strategies	  relating	  to	  ARV	  medicines	  had	  on	  
the	   reputation	   of	   GSK,	   the	   consumer	   and	   capital	   markets	   were	   examined.	   The	   labor	  
market	  wasn’t	  analyzed	  because	  the	  relationship	  between	  reputation	  and	  effect	  on	  labor	  
has	  proven	  difficult	  to	  be	  measured22.	  	  
	  
• Consumer	  Market	  
By	   looking	  at	   the	  total	  sales	  of	  GSK	  between	  2000	  and	  2004,	   it	  does	  not	  seem	  that	  the	  
issue	   peculiarly	   affected	   the	   company.	   The	   total	   sales	   grew	   steadily	   throughout	   the	  
years	   (exhibit	   4).	   In	   2001	   in	   particular,	   the	   year	   when	   the	   incidents	   with	   Oxfam	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  Smith	  &	  Duncan	  2009	  
22	  van	  Tulder	  &	  van	  der	  Zwart	  2005	  
Public	  
	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Private	  
Profit	  
	  
Non	  –	  Profit	  
Efficiency	  
	  
Ethics	  /	  Equity	  
The	  production	  and	  distribution	  
of	  ARVs	  requires	  doing	  business	  
with	  governments	  in	  developing	  
countries	  -­‐	  Cooperate	  with	  
governments	  even	  though	  they	  
might	  be	  corrupt?	  




Africa	  is	  the	  largest,	  but	  
also	  the	  poorest,	  market	  
for	  medicines	  
Is	  the	  right	  to	  accessible	  
healthcare	  a	  universal	  
human	  right?	  
Relationship	  with	  institutions	  
like	  the	  UN,	  WHO,	  World	  Bank,	  






GSK	  is	  market	  leader	  in	  
HIV/AIDS	  
Should	  the	  absence	  of	  a	  
functioning	  State	  imply	  a	  
wider	  moral	  responsibility	  
upon	  MNEs	  and	  their	  home	  
states?	  
Dealing	  with	  IPRs	  and	  
International	  Agreements	  -­‐	  
Patents	  and	  the	  role	  of	  the	  WTO	  
	   Different	  prices	  for	  
different	  geographical	  
markets?	  
HIV/AIDS	  has	  a	  great	  
impact	  on	  the	  economies	  of	  
developing	  countries	  
	   	   Patents	  protect	  R&D	  
investments	  efficiently	  
	  
Transparency	  needed	  in	  
regards	  to	  pricing	  of	  ARVs	  
	   	   	   Free	  trade	  vs.	  the	  
availability	  of	  medicines	  as	  
a	  human	  right	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occurred	   and	   gained	   international	   dimension,	   the	   company’s	   turnover	   increased	  
markedly	  (around	  11	  percent)23.	  Nevertheless,	  it	  is	  important	  to	  bear	  in	  mind	  that,	  since	  
GSK	   has	   a	   strong	   position	   in	   the	   market	   and	   there	   exists	   a	   dependency	   relationship	  
between	   the	   “ill	   people”	   and	   the	   medicines,	   a	   decline	   was	   not	   really	   awaited.	   	   In	  
addition,	   as	  GSK	  has	   a	  wide	   range	   of	   products,	   it	   is	   necessary	   to	   analyze	   the	   antiviral	  
(AV)	  sales	  in	  particular.	  Still,	  profits	  in	  2001	  were	  significantly	  lower,	  which	  could	  result	  
from	  the	  price-­‐cuts	  the	  company	  actively	  started	  to	  implement	  in	  2001.	  
	  
The	  AV	  sales	  for	  HIV	  in	  the	  USA,	  Europe	  and	  Rest	  of	  the	  World	  increased	  along	  the	  years,	  
by	   around	   12-­‐14	   percent	   annually.	   Notwithstanding,	   the	   sales	   of	   antiviral	   drugs	  
decreased	   in	   the	  USA	   in	  2003,	   and	   the	   year	   of	   2004	   showed	   also	   some	  problems:	   the	  
USA	  faced	  a	  decrease	  in	  HIV	  sales	  once	  again,	  in	  Europe	  the	  sales	  only	  grew	  2	  percent,	  in	  
comparison	   to	  double	  digit	  numbers	   in	   the	  previous	  years,	   and	  GSK	   total	   sales	  of	  HIV	  
drugs	  increased	  only	  by	  4	  percent,	  in	  relation	  to	  previous	  years.	  	  
	  
Whether	  the	  variation	  of	  the	  sales	  figures	  can	  be	  connected	  to	  the	  HIV/AIDS	  patenting	  
issues	  and	  lawsuits	  remains	  unclear,	  but	  probable.	  	  
	  
• Capital	  Market	  
GSK’s	  share	  price	  is	  analysed	  in	  relation	  to	  the	  FTSE	  index	  for	  some	  crucial	  dates	  of	  the	  
HIV/AIDS	  pricing	  and	  patenting	  dispute.	  	  
	  
To	   what	   concerns	   the	   South	   African	   dispute	   in	   particular,	   the	   announcement	   of	   the	  
lawsuit	  by	  a	  group	  of	  pharmaceutical	   firms	   in	  March	  2001	   led	  to	  heavy	  drops	   in	  stock	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  Annual	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  2003,	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Source:	  Data	  retrieved	  from	  Bloomberg	  on	  May	  10th	  2013,	  Serie	  GSK	  US	  Equity  
	  
During	  the	  first	  two	  weeks	  of	  the	  month	  of	  March,	  GSK’s	  stock	  price	  suffered	  a	  notorious	  
decrease.	   Whether	   the	   variation	   of	   the	   stock	   price	   can	   be	   connected	   to	   the	  
announcement	  of	  the	  lawsuit	  by	  a	  group	  of	  pharmaceutical	  firms	  in	  March	  2001	  remains	  
unclear,	   as	   there	   can	   be	   other	   factors	   that	   influenced	   the	   stock	   price,	   but	   probable.	  	  
Regarding	   the	   announcements	   of	   GSK	   on	   price	   cuts,	   the	   table	   below	   shows	   that	  
investors	   do	   not	   negatively	   correct	   low-­‐pricing	   behaviour,	   because	   some	  
announcements	  are	  met	  with	  a	  positive	  reaction	  and	  others	  with	  a	  negative	  one.	  
	  






22nd	  February	  2001	  –	  Price	  cut	  of	  
HIV	  medicine	  
+	  2.34%	   +	  0.34%	  
11th	  June	  2001	  –	  Extension	  of	  the	  
low	  pricing	  policy	  
-­‐	  0.61%	   -­‐1.36%	  
20th	  June	  2002	  –	  Two	  –year	  price	  
freeze	  on	  HIV/Aids	  medicines	  
-­‐0.14%	   -­‐1.50%	  
6th	  September	  2002	  –	  Another	  price	  
cut	  
+1.34	   +2.13	  
Source:	  UK	  Finance	  Yahoo	  FTSE	  index	  
	  
Nevertheless,	   the	   Pharmaceutical	   Shareowners	   Group	   (PSG)	   expressed	   deep	   concern	  
about	   the	   reaction	   of	   the	   pharmaceutical	   sector	   to	   the	   HIV/AIDS	   crisis	   (price	   cuts),	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believing	   it	   will	   have	   a	   long-­‐term	   effect	   in	   shareholder	   value24.	   In	   addition,	   concerns	  
regarding	   CSR	   issues	   and	   reputation	   effects	   on	   staff	   morale	   and	   recruitment	   process	  
arose.	   According	   to	   the	   PSG25,	   the	   pharmaceutical	   industry	   is	   based	   on	   knowledge	  
workers,	   which	   are	   characterized	   as	   being	   sensitive	   to	   criticisms	   from	   friends	   and	  
family	   about	   “unethical	   companies”,	   and	   due	   to	   that	   companies	   need	   to	   be	   proactive	  
addressing	   the	   issues,	   otherwise	   they	   can	   have	   an	   impact	   on	   the	   company’s	   labor	  
market.	  	  
GSK	  Change	  in	  Strategy	  
The	   access	   to	   medicines	   issue	   has	   become	   a	   strategic	   consideration	   for	   every	   major	  
pharmaceutical	   company.	   Bridging	   strategies,	   which	   consist	   of	   interaction	   patterns	  
between	  the	  firm	  and	  stakeholders,	  reduce	  the	  opportunity	  for	  further	  attack	  by	  clearly	  
explaining	   their	   actions	   and	   engaging	   in	   stakeholder	   dialogue	   to	   correct	   irresponsible	  
behaviours.	  In	  the	  specific	  case	  of	  GSK,	  the	  CEO	  Jean-­‐Pierre	  Garnier	  (exhibit	  5),	  after	  the	  
activists’	  manifestations	  during	  the	  company	  annual	  meeting	  in	  2001,	  realized	  that	  the	  
criticism	   could	   be	   turned	   around	   and	   acted	   in	   an	   unparallel	   way,	   suggesting	   the	  
company’s	  priority	  was	  public	  health,	  not	  simply	  shareholder	  value:	  
	  
“Some	  months	  ago,	  when	  the	  newly	  merged	  GlaxoSmithKline	  was	  formed,	  I	  said	  that	  I	  did	  
not	  want	  to	  be	  head	  of	  a	  company	  that	  caters	  only	  to	  the	  rich.	  I	  made	  access	  to	  medicines	  
in	   poorer	   countries	   a	   priority	   and	   take	   this	   opportunity	   to	   renew	   that	   pledge.	  We	   have	  
110,000	   people	   who	   go	   to	   work	   every	   morning	   because	   they	   are	   pro-­public	   health.	  We	  
have	   to	  make	   a	   profit	   for	   our	   shareholders	   but	   the	   primary	   objective	   of	   any	   policy	   put	  
forward	  in	  the	  industry	  is	  public	  health26.”	  
	  
By	   suggesting	   that	   the	   company’s	   priority	  was	   public	   health,	   the	   company	   identified	  
the	   points	   of	   intersection	   between	   society	   and	   the	   corporation,	   as	   suggested	   by	  
Porter	   &	   Kramer	   (2006).	   The	   expression	   of	   such	   a	   vision	   was	   uncharacteristic	   for	   a	  
pharmaceutical	   industry	   executive	   and	   this	   quote	   suggests	   a	   clear	   choice	   by	   the	  
company	  of	  the	  social	  issue	  to	  address,	  and	  a	  normative,	  moral	  basis	  response	  to	  the	  
access	  issue.	  However,	  it	  can	  be	  argued	  that	  there	  were	  mixed	  motives	  (normative	  and	  
business)	  for	  GSK’s	  response	  to	  the	  issue,	  such	  as	  that	  this	  action	  was	  needed	  to	  make	  a	  
profit	   for	   shareholders	   since,	   for	   example,	   it	   avoids	   a	   potential	   scenario	   where	   the	  
industry’s	  business	  model	  is	  changed	  and	  government	  regulation	  controls	  every	  action.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
24	  	  Stancich	  2004	  
25	  Pharmaceutical	  Shareowners	  Group	  2004	  
26	  Smith	  &	  Duncan	  2005	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In	  addition,	  the	  company’s	  innovative	  business	  models	  and	  flexible	  pricing	  help	  people	  
get	   the	   vaccines	   and	   medicines	   they	   need	   while	   building	   the	   company’s	   business	   –	  
particularly	  in	  emerging	  markets	  –	  by	  increasing	  the	  overall	  volume	  of	  the	  products	  they	  
sell.	   GSK,	   that	   at	   the	   beginning	   adopted	   a	   reactive	   and	   defensive	   approach	   (“don’t	   do	  
things	   wrong),	   had	   to	   discipline	   itself	   during	   the	   course	   of	   the	   conflict,	   integrating	  
inside-­out	   and	   outside-­in	   practices.	   The	   company	   changed	   its	   strategy	   to	   a	  
proactive/interactive	  approach	  to	  CSR,	  consisting	  on	  “doing	  the	  right	  things	  right”.	  The	  
company	   now	   engages	   in	   a	   in/outside-­‐in/out	   business	   orientation,	   establishing	   a	  
dialogue	  with	   stakeholders.	   Externally,	   GSK	  believes	   the	   company	   can	   create	   value	  by	  
acting	   as	   catalyst	   or	   partner	   for	   other	   organizations	   -­‐	   new	   and	   different	   perspectives	  
that	   other	   groups	   can	   bring	   to	   the	   company’s	   thinking	   are	   valued	   and	  GSK	   is	   open	   to	  
working	   with	   research	   charities,	   academia,	   companies	   and	   non-­‐governmental	  
organizations.	  Internally,	  GSK	  firmly	  believes	  that	  it	  will	  gain	  the	  most	  from	  its	  people	  –	  
and	  attract	  the	  best	  –	  by	  helping	  them	  thrive	  as	  individuals.	  The	  company	  aims	  to	  ensure	  
they	   are	   valued,	   supported	   and	   empowered	   to	   be	   successful	   both	   personally	   and	  
professionally,	  wanting	  them	  to	  feel	  proud	  of	  the	  work	  they	  do,	  the	  company	  they	  work	  
for,	   and	   the	   difference	   they	   make.	   The	   table	   below	   shows	   GSK’s	   CSR	   strategic	  
positioning,	  according	  to	  its	  reputational	  damage	  and	  disciplining:	  
Table	  4.	  Positioning	  the	  Reputation	  Mechanism	  -­	  GSK	  
	   	   Reputational	  Damage	  (Correction)	  
	  	  	  	  	  	  	  	  	  	  	  None	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  from	  van	  Tulder	  &	  van	  der	  Zwart	  2005	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GSK	  believed	   that	  operating	   in	  a	   trustworthy	  and	  responsible	  way	  would	  underpin	   its	  
business	  success:	  to	  conduct	   	  the	  corporate	  social	  responsibility	  policy	  to	  help	  address	  
pressing	   global	   health	   problems	   in	   a	   way	   that	   is	   sustainable	   with	   the	   company’s	  
business	   and	   aligned	   with	   its	   values.	   Still,	   how	   a	   company	   develops	   a	   CSR	   strategy	  
should	   demonstrate	   an	   understanding	   of	  whether	   and	  why	   greater	   attention	   to	   some	  
specific	  issues	  is	  worth	  it.	  	  
	  Implementation	  of	  the	  Strategy	  –	  Corporate	  Social	  Agenda	  
Having	   formulated	   the	   CSR	   strategy,	   GSK’s	   abstract	   visions	   of	   CSR	   had	   to	   become	  
concrete,	  meaning	  the	  company	  had	  to	  create	  a	  corporate	  social	  agenda.	  In	  June	  2001,	  
the	   company	   published	   a	   document	   named	   Facing	   the	   Challenge:	   Our	   Contribution	   to	  
Improving	   Healthcare	   in	   the	   Developing	   World27,	   an	   access	   strategy	   focused	   on	   three	  
main	  aspects:	  
-­‐ Specially	  reduced	  prices	  for	  least	  developed	  countries	  and	  sub-­‐Saharan	  Africa;	  
-­‐ Investing	   in	   research	   and	   development	   of	   medicines	   for	   diseases	   that	   are	  
specially	  dominant	  in	  the	  developing	  world;	  
-­‐ 	  Adopting	   a	   leading	   role	   in	   community	   activities	   that	   promote	   effective	  
healthcare.	  	  
	  
Sixty-­‐two	   countries	   were	   to	   be	   provided	   significantly	   discounted	   prices	   on	   HIV/AIDS	  
and	  malaria	  drugs.	  Furthermore,	  the	  company	  offered	  them	  to	  not-­‐for	  profit	  NGOs	  and	  
international	   agencies,	   aid	   groups,	   churches	   and	   charities	   that	   had	   the	   conditions	   to	  
adequately	   monitor	   and	   treat	   patients	   in	   least	   developed	   countries	   and	   Sub-­‐Saharan	  
Africa.	   African	   employers	   that	   supplied	   HIV/AIDS	   care	   straightaway	   to	   their	   staff	  
through	   workplace	   clinics	   were	   also	   provided	   preferential	   prices	   on	   antiretroviral	  
therapies28.	  Besides	  all	  of	  these	  provisions,	  GSK	  underlines	  some	  major	  challenges	  that	  
can	   obstruct	   these	   actions	   in	   developing	   countries,	   such	   as	   the	   conditions	   of	   the	  
facilities,	   logistic	   problems	   and	   culture,	   like	   traditional	   healers,	   herbal	   treatment	   and	  
juju	  (exhibit	  6).	  	  
	  
In	  order	  to	  operationalize	  the	  policy	  and	  measure	  the	  progress,	  another	  team	  inside	  the	  
company	  was	   created.	  Managers	  were	   demanded	   to	   report	   on	   a	   regular	   basis	   on	   the	  
number	   of	   supply	   arrangements	   made	   under	   the	   access	   policy.	   During	   the	   regular	  
meetings	   and	   conference	   calls,	   the	   progress	   on	   access	   was	   discussed	   and	   managers	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
27	  GSK	  2001	  –	  Facing	  the	  Challenge	  
28	  Duncan	  &	  Smith	  2005	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exchanged	  information	  on	  implementation	  difficulties.	  Still	  in	  2001,	  the	  Global	  Fund	  for	  
AIDS,	   Tuberculosis	   and	   Malaria	   (GFATM)	   was	   created.	   One	   year	   after	   the	  
implementation	  of	  Facing	  the	  Challenge,	  GSK	  said29	  it	  has:	  
	  
• Secured	   nearly	   a	   hundred	   arrangements	   to	   supply	   preferentially	   priced	  
HIV/AIDS	   medicines	   to	   31	   countries	   and	   reached	   a	   ten-­‐fold	   increase	   in	  
shipments	  of	  preferentially	  priced	  Combivir	  to	  the	  developing	  world;	  
• Granted	  a	  voluntary	   license	   to	  Aspen	  Pharmacare,	   the	   largest	  drug	  company	   in	  
Africa,	  for	  antiretrovirals	  in	  South	  Africa;	  
• Continued	   support	   for	   35	   clinical	   trials	   involving	  HIV	  medicines	   in	   developing	  
countries	  of	  which	  18	  are	  new,	  and	  started	   the	   first	  human	  clinical	   trials	  of	   its	  
HIV	  candidate	  vaccine;	  
• Dedicated	  its	  R&D	  facility	  at	  Tres	  Cantos	  in	  Spain	  to	  diseases	  of	  the	  developing	  
world;	  
• Supported	   21	   international	   HIV	   education,	   care	   and	   community	   support	  
programmes	   in	   27	   countries	   with	   19	   partners,	   through	   Positive	   Action,	   the	  
Company's	   long-­‐term	  partnership	  with	  HIV/AIDS	   communities	  worldwide	   and	  
launched	  the	  African	  Malaria	  Partnership.	  
	  
Commenting	  on	  the	  company's	  achievements,	  Glaxo’s	  CEO	  Garnier	  said:	  
	  
	  "GSK	  has	  made	  significant	  progress	  towards	  the	  goal	  of	  increasing	  access	  to	  our	  HIV/AIDS	  
medicines	   in	   developing	   countries,	   in	   partnership	   with	   the	   UN,	   the	   WHO,	   community	  
groups,	   pharmaceutical	   companies	   and	   other	   organizations.	   Our	   efforts	  will	   continue	   as	  
we	   apply	   lessons	   learned	   and	   look	   for	   opportunities	   to	   do	   more.	   We	   encourage	   other	  
stakeholders	  to	  also	  play	  their	  part	  through	  embracing	  partnership,	  showing	  political	  will	  
and,	   above	   all,	   committing	   significant	   new	   funding	   to	   address	   the	   long-­term	   challenge	  
of	  improving	  healthcare	  in	  the	  developing	  world".30	  
	  
The	  company	  was	  applauded	  for	  the	  initiatives	  by	  being	  ranked	  in	  various	  CSR	  indices:	  
FTSE4	   Good	   Global	   100	   index,	   which	   was	   created	   in	   2001	   to	   offer	   a	   series	   of	  
transparent,	   rules-­‐based	   and	   pre-­‐screened	   benchmark	   and	   tradable	   indexes;	   and	   the	  
global	   DJSGI,	   established	   in	   September	   1999	   to	   track	   the	   performance	   of	   the	   world’s	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
29	  Evaluate	  2002	  
30	  Evaluate	  2002	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largest	  companies	  that	  lead	  the	  field	  in	  terms	  of	  corporate	  sustainability.	  In	  2004,	  it	  was	  
even	  ranked	  in	  the	  top	  seven	  of	  the	  pharmaceutical	  sector	  in	  the	  DJSGI.	  	  
	  
Also	   in	   2001,	   a	   Corporate	   Social	   Responsibility	   Committee	   was	   established	   with	   the	  
purpose	  of	   focusing	  on	   the	   social	   strategy	  of	   the	   company.	  The	  Committee	  meets	   four	  
times	  a	  year	  and	  receives	  reports	  on	  progress	  in	  four	  areas	  –	  health	  for	  all;	  our	  behavior;	  
our	  people;	  and	  our	  planet.	   	  GSK’s	  Board	  constructively	  challenges	  and	  advices	  on	   the	  
executive	  team’s	  thinking	  and	  decisions	  as	  they	  seek	  to	  deliver	  the	  company’s	  strategic	  
priorities	   in	   a	   responsible	   way.	   The	   company	   then	   reports	   about	   it	   in	   the	   Corporate	  
Social	  Responsibility	  Report.	  Until	   the	  year	  of	  2002,	   the	  company	  referred	  to	   its	  social	  
strategy	  on	  the	  Annual	  Report,	  with	  only	  four	  to	  five	  pages	  dedicated	  to	  it,	  mentioning	  
vaguely	   that	  GSK	  has	   a	   research	  program	   to	  prevent	   and	   treat	  HIV/AIDS,	  malaria	   and	  
tuberculosis,	  and	  talked	  about	  preferential	  pricing	  but	  lacked	  a	  coherent	  framework	  for	  
the	  CSR	  activities.	  In	  addition,	  initiatives	  taken	  by	  the	  company	  regarding	  partnerships	  
and	  programs	  were	  described	  mainly	   in	  terms	  of	  numbers	  (dollars	  spent,	  hours	  spent,	  
among	   others),	   instead	   of	   describing	   the	   processes,	   its	   advancements	   and	   results	  
achieved	  in	  terms	  of	  contribution	  to	  the	  improvement	  of	  people’s	  lives.	  	  	  
	  
Nowadays,	   the	   breadth	   of	   information	   provided	   demonstrates	   GSK’s	   long-­‐term	  
commitment	  to	  addressing	  these	  issues,	  placing	  great	  importance	  on	  not	  only	  what	  they	  
achieve	   but	   also	   how	   they	   achieve	   it.	   This	   includes	   reporting	   on	   sustainability	   in	  
environmental	  health	  and	  safety,	  global	  community	  partnerships,	  improving	  healthcare	  
in	   the	   developing	  world,	   and	   commitment	   to	   society	   and	   the	   environment.	   HIV/AIDS	  
initiatives	   are	   given	   much	   attention,	   with	   “access	   to	   medicines”	   being	   one	   of	   the	  
company’s	   ten	   Corporate	   Responsibility	   Principles,	   adopted	   in	   2003.	   There	   is	   a	   new	  
business	  function	  as	  the	  single	  point	  of	  strategy	  and	  coordination	  of	  access	  to	  medicines	  
is	   part	   of	   the	  market	   access	   strategy,	  with	   board-­‐level	   oversight,	   quantitative	   targets,	  
performance	   evaluation	   and	   engagement	  with	   numerous	   relevant	   stakeholders.	   GSK’s	  
actual	  CEO,	  Andrew	  Witty	  (exhibit	  5),	  even	  said31:	  
	  
	  “We	  in	  big	  pharma	  should	  never	  take	  for	  granted	  our	  right	  to	  exist;	  our	  business	  model	  in	  
not	   written	   in	   any	   country’s	   constitution.	   (…)	   We	   are	   earning	   it	   by	   meeting	   the	  
expectations	  of	  society.	  When	  you	  start	  to	  think	  like	  this,	  you	  see	  the	  world	  differently.”	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CSR	   is	   an	   integral	   part	   of	   the	   business	   and	   the	   company	   has	   incorporated	   a	   social	  
dimension	   to	   its	   value	   proposition	   since	   the	   beginning	   of	   its	   existence,	   making	  
social	  impact	  part	  of	  the	  overall	  strategy:	  “We	  are	  dedicated	  to	  improving	  the	  quality	  of	  
human	  life	  by	  enabling	  people	  to	  do	  more,	  feel	  better	  and	  live	  longer”	  –	  GSK’s	  mission	  
statement.	  There	  are	  also	  code	  of	  conducts	   in	  place	  for	  public	   lobbying,	  marketing	  and	  
bribery	  and	  corruption,	  supported	  by	  monitoring	  and	  enforcement	  mechanisms	  applied	  
to	  employees	  and	  third	  parties.	  	  
	  
GSK	  has	  also	  numerous	  capability	  advancement	  projects	   in	  research	  and	  development,	  
including	  four	  local	  scientific	  research	  partnerships;	  it	  has	  a	  large	  portfolio	  of	  innovative	  
and	   adaptive	   research;	   and	   engaged	   in	   multiple	   relevant	   collaborations	   with	   the	  
commitment	  that	  the	  drugs	  produced	  as	  a	  result	  of	  these	  partnerships	  will	  be	  available	  
to	  disease	  endemic	  countries	  at	  an	  affordable	  price.	  The	  company	  also	   joined	  the	  UN’s	  
“Accelerated	   Access	   Initiative”,	   which	   constitutes	   a	   partnership	   between	   UNAIDS,	   the	  
WHO,	   UNICEF,	   the	   UN	   Population	   Fund,	   the	   World	   Bank	   and	   seven	   pharmaceutical	  
companies,	  through	  which	  drugs	  are	  being	  provided	  at	  discounted	  prices	  in	  poor	  African	  
countries.	   Furthermore,	   it	   has	   strengthened	   supply	   chain	   and	   quality	   management	  
standards	   and	   is	   one	   among	   the	   few	   companies	   that	  work	  with	   local	   governments	   to	  
improve	  pharmaco-­‐vigilance32.	  	  
	  
In	   2009,	   GSK	   and	   Pfizer	   created	   a	   joint	   venture	   by	   the	  merger	   of	   their	   HIV	   divisions,	  
called	  ViiV	  Healthcare,	  with	  the	  purpose	  of	  improving	  the	  two	  companies’	  position	  in	  the	  
HIV	  market	  by	  cutting	  costs,	  sharing	  research	  and	  combining	  sales	  operations33.	  The	  aim	  
of	  ViiV	  is	  to	  focus	  deeper	  than	  any	  company	  has	  done	  before	  in	  HIV/AIDS	  and	  then	  take	  
a	   new	   approach	   to	   deliver	   effective	   and	   new	   HIV	   medicines,	   as	   well	   as	   support	  
communities	   affected	   by	   HIV34.	   The	   three	   strategic	   priorities	   of	   the	   company	   are	  
innovation	  in	  R&D;	  delivering	  a	  business	  today	  that	  is	  built	  for	  the	  long	  term;	  and	  access	  
and	  care.	  
	  
When	   looking	   at	   the	   Access	   to	  Medicine	   Index,	   which	   emerged	   in	   2008,	   on	   the	   three	  
reports	  published	  (2008,	  2010	  and	  2012),	  GSK	  has	  always	  ranked	  first,	  although	  now	  by	  
a	  narrower	  margin	  (exhibits	  7	  and	  8),	  since	  companies	  are	  becoming	  more	  organized	  in	  
their	  approach	  and	  are	  increasingly	  viewing	  access	  as	  a	  strategic	  issue.	  According	  to	  the	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2012	  Report,	   some	   of	   GSK’s	   leading	   practices	   are	   the	   fact	   that	   the	   company	   discloses	  
clinical	   research	  results	  earlier	   than	  other	  companies,	   following	  completion	  of	  studies,	  
rather	  than	  following	  approval	  or	  termination	  of	  the	  medicine;	  has	  an	  open	  Innovation	  
Strategy,	   aiming	   to	   stimulate	   research	   into	   diseases	   of	   the	   developing	   world;	   has	   a	  
commitment	   to	   make	   no	   political	   contributions	   in	   developing	   countries;	   has	   a	   new	  
Developing	   Countries	   and	   Market	   Access	   Unit	   business	   model	   driven	   equally	   by	  
commercial	   and	   social	   objectives	   in	   50	   emerging	   markets	   through	   partnerships,	  
investment	   and	   philanthropy;	   and	   invests	  more	   than	   any	   other	   company	   in	   targeting	  
relevant	  diseases.	  The	  suggested	  improvements	  are	  to	  reveal	  more	  about	  marketing	  and	  
promotional	   programmes;	   to	   increase	   the	   number	   of	   intellectual	   property	   sharing	  
agreements;	   to	  be	  more	   transparent	  about	  drug	  recalls;	   to	  provide	  more	  details	  about	  
the	   criteria	   for	   product	   registration	   in	   relevant	   countries	   and	   the	   status	   of	  marketing	  
approvals	   for	   each	   relevant	   product;	   and	   to	   undertake	   technology	   transfer	   and	   use	  
milestone-­‐based	  agreements	  within	  non-­‐exclusive	  voluntary	  licensing	  activity35.	  	   	  
R&D	  Strategy	  
As	   GSK	   looks	   to	   discover	   and	   develop	   innovative	   new	   medicines	   and	   vaccines,	   the	  
primary	  goal	   is	  do	   this	  safely	  and	  efficiently.	  Over	   the	  years,	   this	  research	  process	  has	  
changed	  and	   regulations	  evolved	  and	  how	   the	  company	  approached	   this	  goal	  has	  also	  
changed.	   In	   2007,	   GSK	   took	   a	   hard	   look	   at	   how	   they	   were	   seeking	   out	   these	   new	  
medicines	  so	  that	  they	  could	  enhance	  their	  ability	  to	  feed	  into	  a	  late	  stage	  pipeline,	  while	  
improving	  the	  returns	  seen	  on	  the	  R&D	  investment.	  	  
	  
As	  R&D	  is	  an	  investment	  opportunity,	  in	  2007	  GSK	  decided	  to	  forget	  about	  R&D	  having	  a	  
fixed	  budget.	   This	  new	  approach	  means	   the	   company	  has	  more	   to	   invest	   in	   late-­‐stage	  
development	   of	   new	   treatments	   in	   patients.	   The	   early	   stages	   of	   R&D	   are	   an	   elective	  
process:	  GSK	  trusts	  the	  talent	  it	  has	  to	  evaluate	  the	  scientific	  opportunities,	  as	  they	  exist.	  
From	  that	  on,	  the	  company	  decides	  to	  invest	  in	  those	  areas	  where	  the	  science	  looks	  to	  be	  
in	  the	  right	  place,	  where	  there	  is	  the	  most	  potential	  to	  find	  new	  medicines	  and	  improve	  
treatments	   for	   patients.	   For	   GSK’s	   discovery	   organizations,	   this	   means	   the	   company	  
goes	  where	   the	   science	   tells	   it	   to	   go,	  where	   the	   science	   is	   right	   for	   discovering	   a	   new	  
medicine	   and	   where	   there	   is	   a	   medical	   need	   because	   there	   are	   either	   no	   existing	  
treatments,	   or	   because	   those	   that	   are	   available	   are	   not	   adequately	   controlling	   all	  
symptoms	  or	  affecting	  the	  disease	  process.	  This	  means	  that	  sometimes	  it	  might	  only	  be	  a	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moderately	   important	   medicine	   in	   terms	   of	   potential	   income,	   but	   a	   significant	  
improvement	  in	  the	  treatment	  of	  a	  less	  common	  medical	  condition.	  
A	  Global	  Response	  
GSK	   recognizes	   that	   access	   to	  medicines	   is	   a	   complex	   and	  multi-­‐faceted	   issue	  with	  no	  
simple	   answer36,	   where	   the	   challenges	   can	   only	   be	   properly	   addressed	   through	  
partnerships	   between	   developed	   and	   developing	   country	   governments,	   international	  
organizations,	   the	   industry	   and	   charitable	   organizations.	   These	   partnerships	   and	  
collaborations	  with	  different	  organizations	  are	   fundamental	  not	  only	   to	  address	  global	  
health	   challenges,	   but	   also	   to	   develop	   the	   company’s	   strategic	   priorities	   of	   growing	   a	  
diversified,	  global	  business	  and	  delivering	  more	  valuable	  products.	  GSK	  has	  a	  lot	  to	  gain	  
from	   the	   expertise	   from	  academia,	   governments,	  NGOs	   and	  other	   companies	   from	   the	  
sector,	  but	  also	  believes	  that	  working	  with	  GSK	  has	  many	  advantages37:	  
	  
• Therapeutic	   focus	   –	   GSK	   has	   small,	   agile	   groups	   of	   scientists,	   allowing	   greater	  
intimacy	  in	  terms	  of	  knowledge,	  resources	  and	  expertise;	  
• Consumer	   leadership	   –	   GSK’s	   brand	   management	   expertise	   is	   driven	   by	  
consumer-­‐insights;	  
• Global	  reach	  –	  GSK	  operates	  in	  114	  countries	  worldwide;	  
• Business	  excellence	  –	  GSK	  has	  the	  resources	  and	  expertise	  to	  enable	  successful	  
approvals,	  launches	  and	  growth;	  
• Partnering	   performance	   –	   GSK’s	   dedicated	   teams	   in	   business	   development	  
manage	  the	  relationship	  from	  the	  signing	  of	  the	  deal	  through	  to	  delivery.	  	  
Some	  suggestions	  given	  by	  the	  company	  in	  order	  to	  overcome	  this	  issue	  are	  increased	  
funding	   –	   developed	   world	   governments	   need	   to	   provide	   additional	   resources	   for	  
healthcare	   in	   the	   developing	   world	   through	   bilateral	   arrangements	   and	   support	   of	  
multilateral	   organizations;	   retention	   of	   healthcare	   workers	   –	   trained	   healthcare	  
workers	   are	   a	   precious	   commodity;	   price	   and	   product	   protection	   –	   developed	  
countries	   must	   not	   use	   the	   preferential	   prices	   offered	   to	   the	   developing	   world	   as	  
benchmarks	   for	   their	   domestic	   drug	   prices;	   greater	   political	   commitment	   –	  
developing	   world	   governments	   need	   to	   show	   political	   commitment	   	   by,	   for	   example,	  
removing	   import	   tariffs	   that	   increase	   prices;	   strategic	   guidance	   and	   support	   by	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international	   organizations	   –	   organizations	   like	   UNAIDS	   and	   the	   WHO	   have	   an	  
important	  role	  to	  play	  in	  providing	  strategic	  guidance	  and	  providing	  technical	  assistance	  
to	   countries,	   and	  NGOs	  play	  an	   important	   role	   in	  delivering	  healthcare	   to	   some	  of	   the	  
poorest	  people;	  an	  appropriate	  role	   for	  generics	  –	  generic	  companies	  have	  a	  role	   in	  
addressing	  the	  AIDS	  crisis	  but,	  as	  there	  is	  no	  cure	  yet,	  new	  medicines	  and	  vaccines	  are	  
needed.	  Intellectual	  property	  protection	  is	  of	  critical	  importance	  to	  the	  R&D	  industry.	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Exhibit	  2	  –	  South	  African	  Medicines	  and	  Related	  Substances	  Act	  of	  1997	  
	  
Source:	  Fisher	  &	  Rigamonti	  2005	  	  
	  







































Source:	  International	  Programs	  Center,	  Population	  Division,	  US	  Census	  HIV/AIDS	  
Surveillance	  Data	  Base,	  June	  2000	  
	  
	  
Exhibit	  4	  -­‐	  GSK	  Sales	  
	  
GSK Total Sales      
      
Year 2000 2001 2002 2003 2004 
Total Sales (£) 18 079 20 489 21 212 21 441 20 359 
Growth (CER%)   11,0 7,0 5,0 1,0 
      
      
AntiVirals Sales 
Total      
      
Year 2000 2001 2002 2003 2004 
AV Total Sales (£) 1 899 2 128 2 299 2 349 2 360 
Growth (CER%)   10,0 12,0 5,0 8,0 
AV Sales – HIV (£) 1 145 1 347 1 465 1 508 1 463 
Growth (CER%)   14,0 13,0 6,0 4,0 
      
 
AntiVirals Sales 
USA      
      
Year 2000 2001 2002 2003 2004 
AV Total Sales (£) 917 1 071 1 213 1 159 1 165 
Growth (CER%)   11,0 18,0 4,0 12,0 
AV Sales – HIV (£) 686 794 857 798 747 
Growth (CER%)   11,0 12,0 2,0 4,0 
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AntiVirals Sales 
Europe     
      
Year 2000 2001 2002 2003 2004 
AV Total Sales (£) 531 589 636 726 725 
Growth (CER%)   9,0 7,0 5,0 1,0 
AV Sales – HIV (£) 345 405 462 555 559 
Growth (CER%)   16,0 13,0 11,0 2,0 
      
AntiVirals Sales 
Rest of the World / International   
      
Year 2000 2001 2002 2003 2004 
AV Total Sales (£) 451 468 450 464 470 
Growth (CER%)   8,0 6,0 7,0 7,0 
AV Sales – HIV (£) 114 148 146 155 157 
Growth (CER%)   31,0 16,0 12,0 8,0 
	  Note:	  In	  order	  to	  illustrate	  underlying	  performance,	  it	  is	  the	  Group’s	  practice	  to	  discuss	  its	  results	  in	  terms	  
of	  constant	  exchange	  rate	  (CER)	  growth.	  This	  represents	  growth	  calculated	  as	  if	  the	  exchange	  rates	  used	  to	  
determine	   the	   results	   of	   overseas	   companies	   in	   sterling	   had	   remained	   unchanged	   from	   those	  
used	  in	  the	  previous	  year.	  	  
	  
Source:	  GSK	  Annual	  Reports	  –	  2000,	  2001,	  2002,	  2003	  and	  2004	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Exhibit	  6	  -­‐	  The	  Challenges	  in	  the	  Developing	  World	  
-­‐ Challenges	  in	  Facilities	  
	  
There	   is	  a	   chronic	  under-­‐investment	   in	  healthcare	   facilities,	  which	  has	   led	   to	  a	   lack	  of	  
clinics	   and	   hospitals,	   low	   numbers	   of	   trained	   healthcare	   providers,	   and	   high	   levels	   of	  
patient	  illiteracy.	  
	  
-­‐ Challenges	  in	  Logistics	  
	  
The	   distribution	   networks	   are	   very	   poor	   and	   the	   unavailability	   of	   medicines	   in	  
particular	   can	   be	   caused	   by	   logistical	   supply	   and	   storage	   problems.	   In	   addition,	   the	  
transportation	  phase	  of	  the	  supply	  chain	  needs	  to	  account	  for	  the	  robbery	  of	  the	  drugs.	  
	  









Cultural	   factors	  such	  as	   traditional	  healers,	  herbal	   treatment,	   juju	   (an	  object	  used	  as	  a	  
mean	  of	  protection),	  stigma	  and	  discrimination	  also	  limit	  access	  to	  medicines.	  	  
	  
Source:	  Facing	  the	  Challenge	  2001
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Exhibit	  7	  –	  The	  Access	  to	  Medicine	  Index	  2012	  Overall	  Ranking	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Exhibit	  8	  -­‐	  The	  Access	  to	  Medicine	  Index	  2012	  GSK	  Ranking	  
	  
	  
Source:	  Access	  to	  Medicine	  Index	  Report	  2012	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Chapter	  5	  -­‐	  Teaching	  Notes	  
Case	  Summary	  
Elected	   president	   of	   South	   Africa	   in	   1994	   after	   the	   first	   democratic	   elections,	   Nelson	  
Mandela	  had	  as	   a	  priority	  on	   the	   agenda	  of	   the	  post-­‐apartheid	   government	   to	  make	  a	  
health	  care	  reform,	  since	  many	  South	  Africans	  did	  not	  have	  access	  to	  health	  care	  at	  all.	  	  
As	  so,	   in	  1997	  signed	  the	  Medicines	  and	  Related	  Substance	  Act,	  which	  allowed	  parallel	  
importing	   -­‐	   such	   as	   importing	   pharmaceuticals	   from	   any	   origin,	   admitting	   generic	  
manufacturers	   careless	   of	   whether	   the	   patent	   holders	   approved,	   generating	   less	  
expensive,	  generic	  drugs	  available	  to	  the	  citizens	  -­‐	  and	  compulsory	  licensing	  -­‐	  gives	  the	  
government	   the	   opportunity	   to	   grant	   local	   companies	   authorization	   to	   fabricate	  
generics	  even	  when	  valid	  patents	  were	  held	  by	  foreign	  companies	  -­‐	  in	  order	  to	  harness	  
the	  HIV/AIDS	  pandemic	  in	  South	  Africa,	  which	  further	  contributed	  to	  the	  magnitude	  of	  
the	   health	   care	   problem.	   GSK	   and	   other	   large	   pharmaceutical	   companies	   considered	  
both	   provisions	   in	   the	   Act	   as	   an	   assault	   on	   its	   IPR	   and	   filed	   a	   lawsuit	   against	   the	  
government	   of	   South	   Africa.	   Media	   attention	   and	   international	   public	   pressure	   on	  
pricing	  policies	  for	  patented	  drugs	  increased	  at	  that	  time	  and	  pharmaceutical	  companies	  
ended	  up	  agreeing	  on	  dropping	  the	  case	  against	  the	  South	  African	  government.	  Despite	  
the	  withdrawal	  from	  the	  South	  African	  case,	  the	  pharmaceutical	  industry	  in	  general,	  and	  
GSK	  in	  particular,	  kept	  being	  publicly	  criticized,	  with	  critical	  stakeholders	  demanding	  a	  
change	  in	  the	  corporate	  behaviour	  of	  GSK.	  The	  South	  African	  court	  case	  and	  the	  access	  
problem	  demonstrated	  an	  industry	  in	  crisis	  concerning	  the	  scope	  and	  meaning	  of	  social	  
responsibility.	  
Learning	  Objectives	  
The	   case	   study	   was	   developed	   for	   students	   interested	   in	   the	   fields	   of	   strategy	   and	  
development,	  or	  students	  attending	  courses	  related	  to	  strategy,	  which	  incorporate	  CSR	  
as	  a	   teaching	  topic.	  The	  case	  gives	  the	  opportunity	  to	   learn	   important	  strategy	   lessons	  
not	  only	  in	  general,	  but	  also	  in	  the	  pharmaceutical	  industry	  in	  particular.	  	  
	  
The	  main	  goals	  of	  the	  teaching	  case	  are:	  
• To	  give	  students	  an	  increased	  awareness	  of	  Africa’s	   HIV/AIDS,	   tuberculosis,	  
malaria	   and	   neglected	   diseases	   problems,	   and	  some	  of	  its	  health	   systems’	  
most	  challenging	  barriers:	  infrastructures,	  logistics	  and	  culture;	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• To	  make	  students	  understand	  how	  compulsory	  licensing	  and	  parallel	  importing	  
decisions	   made	   by	   governments	   in	   these	   countries	   can	   become	   challenging	  
measures	  for	  the	  pharmaceutical	  industry	  in	  particular;	  
• To	  lead	  the	  discussion	  about	  CSR	  relevance	  and	  applicability	  and	  how	  it	  should	  
be	  handled	  in	  order	  to	  create	  social	  and	  economic	  value	  at	  the	  same	  time;	  
• To	   comprehend	   corporate	   motives	   for	   CSR	   and	   to	   what	   extent	   can	   CSR	   be	  
considered	  relevant	  as	  a	  strategic	  corporate	  driver	  and	  be	  aligned	  with	  current	  
business	  practices	  and	  core	  objectives;	  
• To	   understand	   the	   importance	   of	   strategic	   partnerships	   while	   working	   in	  
healthcare	  and	  in	  Africa.	  	  
Teaching	  Questions	  and	  Case	  Discussion	  
 TQ1:	  What	   are	   the	  main	   sources	   of	   corporate	  motives	   for	   CSR	   that	   you	   can	   identify,	  
according	  to	  Porter	  &	  Kramer	  (2006)?	  Do	  you	  consider	  "giving	  back	  to	  society"	  the	  only	  
reason	  why	  GSK	  engages	  in	  CSR?	  	  
	  
In	   agreement	   with	   Smith	   (2003),	   corporate	   attention	   to	   CSR	   can	   come	   from	   three	  
different	   scenarios:	   	   the	   normative	   case,	   which	   comes	   from	   a	   desire	   to	   do	   good;	   the	  
business	   case,	   where	   there	   is	   an	   enlightened	   self-­‐interest;	   or	   a	   mixture	   of	   these	   two	  
motivations.	   The	   four	   prevailing	   corporate	   motives	   for	   CSR,	   according	   to	   Porter	   &	  
Kramer	   (2006)	   are:	   moral	   obligation,	   which	   comes	   from	   the	   duty	   to	   be	   a	   good	  
corporate	   citizen	   and	   to	   “do	   the	   right	   things”;	   sustainability,	   that	   relates	   to	  
environmental	   and	   community	   stewardship;	   license	   to	   operate,	   which	   refers	   to	   the	  
permission	  to	  do	  business	  from	  governments,	  communities	  and	  other	  stakeholders;	  and	  
reputation,	   since	   CSR	   initiatives	   improves	   a	   company’s	   image,	   among	   other	   things.	  
Although	   these	   justifications	   have	   advanced	   thinking	   in	   the	   field,	   it	   is	   important	   to	  
underline	  that	  none	  offers	  sufficient	  guidance	  for	  the	  difficult	  choices	  corporate	  leaders	  
must	  make.	  
	  
Zooming	  into	  GSK	  in	  particular,	  during	  the	  company’s	  annual	  meeting	  in	  2001,	  the	  CEO	  
Jean-­‐Pierre	  Garnier	  stated	  that	  the	  company’s	  priority	  was	  public	  health	  and	  not	  simply	  
shareholder	  value.	  By	  simply	  looking	  at	  this	  statement,	  one	  could	  consider	  “giving	  back	  
to	   society”	   the	   only	   reason	   why	   GSK	   engages	   in	   CSR.	   However,	   when	   analyzing	   the	  
events	  the	  company	  went	  through	  regarding	  the	  access	  to	  medicines	  vs.	  IPR	  issue,	  it	  can	  
be	   argued	   that	   there	   were	   mixed	   motives	   (normative	   and	   business)	   for	   GSK’s	  
engagement	  in	  CSR.	  Media	  attention	  on	  pricing	  polices	  for	  patented	  drugs	  increased	  at	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the	  time	  of	  the	  South	  African	  lawsuit,	  NGOs	  took	  advantage	  of	  that	  and	  started	  to	  launch	  
campaigns	   with	   great	   impact	   for	   drug	   giants	   to	   cut	   the	   costs,	   and	   in	   the	   US	   critical	  
stakeholders	   also	   started	   to	   demand	   a	   change	   in	   the	   corporate	   behaviour	   of	   the	  
company.	   In	   addition,	   despite	   the	   withdrawal	   from	   the	   South	   African	   case,	   the	  
pharmaceutical	  industry	  in	  general	  and	  GSK	  in	  particular	  kept	  being	  publicly	  criticized.	  
GSK’s	   overall	   reputation	  was	   demonstrably	   damaged	   and	   a	   response	   by	   the	   company	  
was	  needed	  to	  guarantee	  a	  profit	  for	  shareholders.	  Martin	  (2002)	  has	  noticed	  that	  firms	  
frequently	   engage	   in	  CSR	   “precisely	  because	   it	   enhances	   shareholder	  value”	   and	   some	  
CSR	  activities	  “create	  goodwill	  among	  consumers	  in	  excess	  of	  their	  price	  tag”. As	  so,	  one	  
can	  say	  GSK’s	  attention	  to	  CSR	  came	  from	  an	  enlightened	  self-­‐interest	  and	  a	  desire	  to	  do	  
good.	  	  
 
TQ2:	   CSR	   can	   have	   a	   positive	   impact	   on	   profitability.	   Comment	   this	   statement	   and	  
justify	  your	  answer	  with	  an	  example	  from	  GSK.	  	  
	  
In	   this	   case,	   the	  Professor	   should	   start	   by	   remarking	   that	   there	   is	   no	   clear	   conclusion	  
that	   CSR	   has	   a	   positive	   impact	   on	   a	   company’s	   profitability	   but	   that	   studies	   point	   for	  
companies	  that	  engage	  in	  CSR	  not	  to	  underperform.	  This	  could	  also	  be	  suggested	  as	  an	  
academic	  challenge	  and	  possible	  theme	  for	  students	  interested	  in	  research	  in	  this	  field.	  	  
Regarding	  GSK’s	  case,	  and	  concerning	  reputation,	  one	  can	  associate	  CSR,	  or	  the	  lack	  of	  it,	  
with	   the	   reputational	   damage	   the	   company	   faced	   during	   and	   after	   the	   South	   African	  
lawsuits,	   which	   could	   consequently	   lead	   to	   a	   negative	   impact	   on	   profitability.	   	   The	  
change	  of	  CSR	  and	  overall	  market	  strategy	  from	  that	  time	  on	  can	  be	  associated	  with	  the	  
company	  being	  ranked	  in	  various	  CSR	  indices	  for	  its	  initiatives:	  FTSE4	  Good	  Global	  100	  
index	   and	   the	   global	   DJSGI.	   In	   2004,	   it	   was	   even	   ranked	   in	   the	   top	   seven	   of	   the	  
pharmaceutical	   sector	   in	   the	   DJSGI.	   This	   association	   of	   the	   corporate	   image	   to	   social	  
causes	   can	   have	   a	   positive	   impact	   on	   reputation	   and	   consumer	   loyalty.	   In	   terms	   of	  
employee	  morale	  and	  loyalty,	  there	  is	  also	  the	  perception	  and	  the	  intention	  that	  this	  was	  
enhanced	  as,	  for	  example,	  African	  employers	  that	  supplied	  HIV/AIDS	  care	  straightaway	  
to	   their	   staff	   through	   workplace	   clinics	   were	   provided	   preferential	   prices	   on	  
antiretroviral	   therapies	  by	   the	   company.	  Finally,	   it	  has	   strengthened	  supply	   chain	  and	  
quality	   management	   standards	   and	   is	   one	   among	   the	   few	   companies	   that	   work	   with	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TQ3:	   In	   what	   sense	   do	   you	   consider	   that	   leadership	   in	   GSK	   influenced	   its	   CSR	  
commitment?	  	  
	  
This	  question	   includes	  some	  concepts	  about	   leadership	   that	  can	  be	  approached	  by	  the	  
professor	  in	  class,	  mainly	  transformational	  leadership.	  Transformational	  leadership	  is	  a	  
leadership	  style	  that	  leads	  to	  positive	  changes	  in	  those	  who	  follow,	  as	  people	  will	  follow	  
a	  person	  who	  inspires	  them.	  The	  way	  to	  get	  things	  done	  is	  by	  injecting	  enthusiasm	  and	  
energy	   and	   followers	   will	   also	   be	   “transformed”	   and	   learn	   from	   the	   process	   (“I	   care	  
about	   your	   self	   accomplishment”).	   Transformational	   leadership	   consists	   of	   four	  
dimensions:	   charisma	   –	   instilling	   pride	   and	   trust;	   inspiration	   –	   communicating	   high	  
expectations,	   a	   vision;	   intellectual	   stimulation	   –	   promoting	   intelligence	   and	   careful	  
problem	   solving;	   and	   individualized	   consideration	   –	   providing	   personal	   attention	   and	  
coaching.	  	  
	  
When	   Jean-­‐Pierre	  Garnier	   became	  CEO	   of	   GSK	   in	   2000,	   he	   had	   a	   rocky	   road	   ahead	   of	  
him,	  as	  he	  had	  to	  reconcile	  two	  different	  corporate	  cultures,	  criticism	  from	  consumers,	  
shareholders	   and	   civil	   society,	   and	   some	   of	   the	   worst	   drug	   pipelines	   in	   the	  
pharmaceutical	   industry.	   Garnier	   adopted	   a	   corporate	   structure	   that	   combined	  
traditional	   activities	   with	   innovative	   strategies,	   as	   he	   wanted	   to	   company	   to	   remain	  
flexible	  enough	  to	  grasp	  new	  opportunities	  and	  remain	  competitive.	  Few	  CEOs	  can	  work	  
with	  shareholders	  as	  effortlessly	  as	  Garnier,	  as	  he	  is	  the	  kind	  of	  person	  who	  dominates	  a	  
room	  and	  is	  well	  aware	  of	  that,	  and	  rivals	  have	  copied	  many	  of	  his	  reforms.	  In	  November	  
2006,	   during	   an	   interview	   to	   the	   Financial	   Times,	   Garnier	   clearly	   demonstrated	   his	  
profile	  of	  a	  transformational	  leader:	  
	  
“I	  don't	  see	  myself	  as	  a	  manager	  I	  see	  myself	  as	  a	  leader.	  I	  get	  people	  aligned	  with	  my	  views	  
show	   them	   the	  passion	   I	  have	  and	   that	   they	   can	  be	  part	  of	  an	   exciting	  venture.	   It's	   very	  
important	  that	  you	  state	  the	  goal	  in	  terms	  that	  are	  exciting.	  If	  you	  say	  "	  let's	  get	  another	  
two	  points	  on	  the	  margin,	  they	  won't	  follow"”	  
	  
	  In	   the	  CSR	   field	   in	  particular,	  Garnier,	   through	   the	  application	  of	   the	   frameworks	   that	  
guide	   the	   core	   business	   choices	   of	   the	   company,	   analysed	   the	   prospects	   for	   social	  
responsibility	  and	  came	   to	   the	  conclusion	   that	  CSR	  could	  be	  much	  more	   than	  a	  cost,	  a	  
constraint	   or	   a	   charitable	   need.	   He	   saw	   it	   as	   a	   source	   of	   opportunity,	   innovation	   and	  
competitive	   advantage,	   since	   the	   business	   puts	   in	   practice	   resources,	   expertise	   and	  
insights	  to	  activities	  that	  benefit	  society.	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Among	  the	  enormous	  amount	  of	  social	  issues	  that	  the	  pharmaceutical	  industry	  is	  called	  
to	   address,	   Garnier	   realized	   that	   developing	   an	   access	   to	   medicines	   strategy	   could	  
symbolize	  a	  real	  opportunity	  to	  make	  a	  difference	  to	  society	  and	  to	  achieve	  competitive	  
advantage,	  as	  nowadays	  competitiveness	  has	  increased	  and	  more	  and	  more	  companies	  
meet	   the	   quality	   requirements	   of	   the	  market.	   Consumers	  will	   differentiate	   companies	  
through	   the	  way	   the	  company	  behind	   the	  product	  or	   service	   stands	   for	   in	   society	  and	  
CSR	   might	   make	   a	   significant	   difference	   at	   the	   margin	   of	   many	   firms.	   Garnier	   is	   in	  
particular	   credited	   with	   forging	   a	   compromise	   over	   the	   row	   about	   the	   price	   of	   HIV	  
medicines	   for	   African	   countries,	   as	   he	   helped	   forge	   agreement	   on	   the	   controversial	  
issue,	  with	  GSK	  becoming	  the	  first	  big	  drugs	  company	  to	  offer	  not-­‐for	  profit	  HIV	  drugs.	  	  
	  
TQ4:	   Falck	   &	   Heblich	   (2007)	   developed	   a	   framework	   to	   decide	   which	   stakeholders	  
should	   be	   considered	   and	   how	  much	   is	   at	   stake	   when	   considering	   an	   issue.	   Can	   you	  
apply	  it	  to	  GSK	  and	  the	  access	  to	  medicines	  issue?	  
	  
In	  order	  to	  answer	  this	  question,	   the	  Professor	  should	  present	  Falck	  &	  Heblich	  (2007)	  
framework,	  as	  shown	  in	  the	  figure	  below,	  where	  GSK’s	  path	  is	  described	  in	  red:	  
 
Figure 3. Falck & Heblich (2007) Framework adapted to GSK	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The	   decision	  making	   process	   started	   by	   a	   social	   trend,	   the	   access	   to	  medicines	   issue,	  
which	  was	  evaluated	  by	  the	  company	  (the	  first	  step	  of	  strategic	  planning)	  in	  order	  to	  see	  
if	  it	  could	  achieve	  significant	  dimensions.	  As	  the	  claim	  came	  not	  only	  from	  NGOs,	  which	  
are	  emerging	  stakeholders,	  but	  also	  from	  key	  stakeholders	  in	  the	  USA,	  as	  shown	  in	  red	  
in	  the	  graph	  below,	  it	  could	  achieve	  significant	  dimensions	  and	  consequently	  affect	  the	  
company.	  	  	  
	  












Applying	   Falck	   &	   Heblich	   (2007)	   cost-­‐benefit	   analysis	   to	   calculate	   the	   expected	   net	  
present	  value	  of	  the	  future	  cash	  flow,	  it	  was	  possible	  to	  conclude	  that	  key	  stakeholders,	  
like	  customers	  and	  key	  suppliers,	  have	  a	  direct	   link	   to	   the	  company	  and	  can	   influence	  
the	  current	  and	  expected	  cash	  flow	  with	  low	  volatility.	  As	  so,	  they	  were	  the	  ones	  to	  be	  
considered	  when	  calculating	  the	  expected	  net	  present	  value	  of	  the	  CSR	  action.	  Emerging	  
stakeholders,	   like	  Oxfam,	  do	  not	  have	  a	   linear	   linkage	  with	  the	  corporation’s	  cash	  flow	  
and	   do	   not	   influence	   the	   expected	   net	   present	   value.	   However,	   they	   can	   become	   key	  
stakeholders	  all	  of	  a	  sudden,	  as	  happened	  during	  GSK’s	  shareholders	  annual	  meeting	  in	  
2001.	  The	  volatility	  of	  their	  expected	  cash	  flow	  is	  high	  and	  therefore	  this	  group	  must	  be	  
monitored	   regularly.	   As	   these	   two	   groups	   of	   stakeholders	  were	   involved	   in	   the	   claim,	  
something	  needed	  to	  be	  done.	  At	  first,	  GSK	  opted	  for	  a	  strategic	  action	  of	  an	  individual	  
commitment	  type,	  which	  granted	  the	  company	  a	  first-­‐mover	  advantage,	  which	  improved	  
the	   company’s	   reputation	   among	   customers	   and	   other	   stakeholders.	   However,	   as	   this	  
issue	  is	  a	  collective	  problem	  for	  the	  pharmaceutical	   industry	  and	  due	  to	  its	   increase	  in	  
dimension,	   it	   became	   a	   collective	   commitment	   and	   a	   structural	   action	   was	   required:	  
competitors	  are	  now	  linked	  to	  this	  code.	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TQ5:	   In	  what	   areas	  do	   you	   consider	   that	  GSK	  has	   changed	   the	  way	   it	   addresses	  CSR,	  
from	  reactive	  to	  proactive?	  
	  
In	   this	   question	   the	   Professor	   can	   base	   the	   discussion	   in	   the	   change	   in	   strategy	   and	  
implementation	  sections	   from	   the	   case	   study,	  where	  a	  detailed	  explanation	  of	   the	  way	  
GSK	  changed	  its	  overall	  strategy	  and	  created	  also	  a	  CSR	  strategy	  was	  developed.	  It	  can	  
also	  be	  discussed	  that,	  regarding	  CSR,	  the	  company	  adopted	  a	  long-­‐term	  position,	  with	  
planning,	  supervision	  and	  evaluation	  on	  a	  regular	  basis.	  	  	  
	  
In	  order	  to	  do	  so,	  GSK,	  according	  to	  Porter	  &	  Kramer	  (2006),	  had	  to	  incorporate	  a	  social	  
perspective	  into	  the	  core	  model	  that	  is	  exercised	  to	  comprehend	  competition	  and	  guide	  
its	  business	  strategy,	  by	   identifying	   the	  points	  of	   intersection	  between	  society	  and	   the	  
corporation,	  choosing	  which	  social	  issues	  to	  address,	  creating	  a	  social	  dimension	  to	  the	  
value	   proposition	   and	   a	   corporate	   agenda,	   and	   integrating	   inside-­‐out	   and	   outside-­‐in	  
practices.	  The	  table	  below	  indicates	  the	  focal	  points	  that	  should	  be	  discussed:	  	  
	  
	  
Table	  5.	  GSK	  Before	  and	  After	  the	  South	  African	  Trade	  Dispute	  
	   Before	  (Reactive)	   After	  (Proactive)	  
Company’s	  
Priority	  
Shareholder	  value	   Public	  health	  and	  shareholder	  value	  
Strategy	  
“Don’t	  to	  things	  wrong”	  –	  outside-in 
approach because the company is 
socially responsive and responds to 
specific actions of external actors that 
could damage their reputation	  
“Do	  the	  right	  things	  right”	  –	  the	  company 
takes on activities aimed at external 
stakeholders right from the start of an issue 
life cycle, allowing the company to act 
quickly to take advantage of the occasion by 
positioning itself at the forefront of an issue 
that may become of major public interest. 
There is an incentive to act proactively so as 
to gain a first-mover advantage and it is also 
interactive because there are “outside in” and 
“inside out” approaches, which complement 
each other	  
CSR	  Report	  
Incorporated	  in	  the	  Annual	  Report	  
with	  only	  a	  few	  pages	  dedicated	  to	  
it,	  where	  the	  initiatives	  taken	  by	  
the	  company	  were	  described	  
mainly	  in	  terms	  of	  numbers	  instead	  
of	  describing	  the	  processes,	  its	  
advancements	  and	  results	  achieved	  
in	  terms	  of	  contribution	  to	  the	  
improvement	  of	  people’s	  lives	  
Created	  a	  Corporate	  Social	  Responsibility	  
Committee	  and	  reports	  about	  it	  in	  the	  
Corporate	  Social	  Responsibility	  Report.	  
HIV	  and	  AIDS	  initiatives	  are	  given	  much	  
attention,	  with	  “access	  to	  medicines”	  being	  
one	  of	  the	  company’s	  ten	  Corporate	  
Responsibility	  Principles,	  adopted	  in	  2003	  




No	  specific	  strategy	  developed	  
The	  single	  point	  of	  strategy	  and	  
coordination	  of	  access	  to	  medicines	  is	  part	  
of	  the	  market	  access	  strategy,	  with	  board-­‐
level	  oversight,	  quantitative	  targets,	  
performance	  evaluation	  and	  engagement	  
with	  numerous	  relevant	  stakeholders.	  
Developed	  Facing	  the	  Challenge,	  with	  a	  
team	  to	  measure	  its	  progress,	  and	  all	  the	  
things	  done	  from	  that	  time	  on	  
	  
	  
TQ6:	  What	   are	   GSK’s	   and	   other	   pharmaceutical	   companies	   main	   challenges	   in	   the	  
developing	  world,	  to	  what	  concerns	  increasing	  access	  to	  medicines?	  
	  
Besides	   all	   of	   the	  provisions	   of	  medicines	   and	   support	  made	   in	   the	  developing	  world,	  
GSK	   underlines	   some	   major	   challenges	   that	   can	   obstruct	   these	   actions	   in	   developing	  
countries.	  First	  of	  all,	  poverty	  is	  the	  single	  biggest	  barrier	  to	  improving	  healthcare,	  as	  in	  
many	   countries	   people	   do	   not	   have	   enough	   food	   or	   access	   to	   a	   clean	   water	   supply.	  
Another	  key	  factor	  is	  a	  chronic	  under-­‐investment	  in	  healthcare	  facilities,	  which	  has	  led	  
to	   a	   lack	   of	   clinics	   and	   hospitals,	   poor	   distribution	   networks,	   low	   numbers	   of	   trained	  
healthcare	   providers,	   and	   high	   levels	   of	   patient	   illiteracy.	   Unavailability	   in	   particular,	  
can	   be	   caused	   by	   logistical	   supply	   and	   storage	   problems.	   Ensuring	   there	   are	   no	  
interruptions	   in	   people’s	   treatment	   demands	   a	   guaranteed	   supply	   of	   antiretroviral	  
drugs	  from	  the	  factories	  where	  they	  are	  produced,	  to	  the	  treatment	  centers	  in	  perhaps	  
remote	   areas	   of	   a	   country.	   Furthermore,	   laboratory	   supplies,	   testing	   kits	   and	  
information	  also	  need	   to	  pass	  along	   the	   supply	   chain.	  The	   transportation	  phase	  of	   the	  
supply	   chain	   requires	   delivery	   tracking	   and	   needs	   to	   account	   for	   potential	   customs	  
barriers.	   In	  unstable	   regions	   in	  particular,	   the	   robbery	  of	   the	  drugs	  may	  be	   a	   concern	  
and	   armed	   escorts	   and	   decoy	   trucks	   are	   known	   to	   protect	   expensive	   deliveries.	  
Intermediate	  storage	  of	  the	  medication	  –	  such	  as	  in	  large	  regional	  warehouses	  –	  needs	  
to	  be	   safe	   and	   secure	  and	  be	  able	   to	   efficiently	  process	  orders	   and	  distribute	  ARVs	   to	  
health	   facilities.	   Similarly,	   local	   facilities	   should	   be	   able	   to	   safely	   and	   securely	   store	  
medication	   at	   controlled	   temperatures.	   All	   of	   these	   requirements	  mean	   that	   the	   costs	  
involved	  in	  distributing	  the	  drugs	  are	  higher	  than	  the	  antiretroviral	  drugs	  themselves.	  	  
	  
Other	   factors	   that	   limit	   access	   to	   medicines	   are	   taxes	   and	   tariffs	   that	   raise	   prices	  
unnecessarily,	   cultural	   factors	   such	   as	   stigma	   and	   discrimination,	   and	   high	   levels	   of	  
corruption	  and	  bribery	  in	  governments.	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TQ7:	   In	   the	   Health	   sector,	   it	   has	   been	   realized	   that	   the	   problems	   most	   difficult	   to	  
manage,	  such	  as	  the	  access	  to	  medicines	  issue,	  need	  new	  ways	  of	  working	  together.	  How	  
do	  you	  think	  partnerships	  can	  be	  part	  of	  the	  solution?	  
	  
In	   order	   to	   answer	   this	   question,	   the	  professor	   can	  base	   the	  discussion	  on	  GSK’s	   case	  
study	   and	   interviews	  made	   to	   GSK	   and	   Bayer	   (appendices	   6	   and	   7),	   where	   plenty	   of	  
partnerships	   with	   governmental	   and	   non-­‐governmental	   organizations	   are	   described.	  
The	  challenge	  of	  answering	  pressing	  healthcare	  issues	  worldwide	  is	  a	  huge	  task	  that	  no	  
aid	   organization,	   government,	   company	   or	   research	   institute	   can	  manage	   alone.	   New	  
ways	   of	   working	   together,	   in	   addition	   to	   better	   coordination	   of	   the	   traditional	   roles,	  
creates	   the	   opportunity	   to	   combine	   the	   strengths,	   resources	   and	   expertise	   of	   the	  
different	   sectors:	   public,	   private	   and	   civil	   society.	   It	   is	   true	   that	   when	   very	   different	  
types	   of	   organizations	   work	   together,	   the	   probability	   of	   clashes	   of	   goals,	   objectives,	  
values,	   cultures,	   strategies,	   management	   styles,	   and	   operating	   approaches	   is	   high.	  
Notwithstanding,	  some	  of	  these	  relationships	  may	  prosper	  and	  turn	  into	  close,	  mutually	  
beneficial	   long-­‐term	   partnerships	   designed	   to	   achieve	   strategic	   goals	   for	   the	   parts	  
involved	  and	  may	  be	  able	  to	  make	  a	  real	  difference.	  	  
GSK	  has	  successfully	  worked	  in	  a	  diverse	  range	  of	  partnerships	  and	  collaborations	  over	  
the	   years,	   and	   is	   always	   looking	   for	   new	   opportunities.	   For	   example,	   in	   2013,	   the	  
company	  has	  launched	  an	  ambitious	  global	  partnership	  with	  Save	  the	  Children	  to	  share	  
its	   expertise	   and	   resources.	   The	   new	   partnership	   goes	   well	   beyond	   the	   traditional	  
charity	   corporate	   fundraising	   model.	   It	   will	   touch	   many	   areas	   of	   GSK’s	   business,	   in	  
particular	  using	  its	  R&D	  capabilities	  to	  help	  save	  children’s	  lives.	  
The	  GSK	  and	  Save	  the	  Children	  partnership	  will	  focus	  in	  particular	  on:	  
 Developing	  child-­‐friendly	  medicines	  to	  reduce	  child	  mortality	  and	  new-­‐born	  deaths;	  
 Widening	  vaccination	  coverage	  to	  reduce	  the	  number	  of	  child	  deaths	  in	  the	  hardest	  to	  
reach	  communities;	  
 Researching	   new	   affordable	   nutritional	   products	   to	   help	   alleviate	   malnutrition	   in	  
children;	  
 Increasing	   investment	   in	   the	   training,	   reach	   and	   scope	   of	   health	   workers	   in	   the	  
poorest	  communities	  to	  help	  reduce	  child	  mortality.	  
	  
Another	   example,	   now	   from	  Bayer	   Health	   Care,	   is	   the	   fight	   against	   neglected	   tropical	  
diseases	  (NTDs),	  which	  threaten	  1.4	  billion	  people	  worldwide;	  the	  poorest	  of	  the	  poor	  in	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developing	  and	  transition	  countries	  are	  particularly	  at	  risk.	  As	  in	  the	  case	  of	  Neglected	  
and	   Tropical	   Diseases,	   the	   fight	   to	   defeat	   these	   diseases	   and	   improve	   people's	   living	  
conditions	   particularly	   in	   poor	   endemic	   countries	   can	   only	   be	   won	   as	   part	   of	   a	  
concerted,	  major	   international	   effort.	   In	  2012,	   thirteen	  pharmaceutical	   companies,	   the	  
governments	   of	   the	   United	   States,	   the	   UK,	   and	   the	   United	   Arab	   Emirates,	   the	   Bill	   &	  
Melinda	   Gates	   Foundation,	   the	   World	   Bank	   and	   other	   global	   health	   organizations	  
launched	   the	   biggest	   campaign	   to	   date	   in	   the	   fight	   against	   the	   neglected	   tropical	  
diseases.	   The	   aim:	   to	   control	   or	   eradicate	   ten	   neglected	   tropical	   diseases	   in	  
collaboration	  with	  the	  countries	  affected	  by	  2020.	  The	  strength	  of	   the	   initiative	   is	   that	  
renowned	   partners	   with	   global	   influence	   are	   using	   their	   respective	   expertise	   and	  
organizational	   skills	   in	   a	   concerted	   action	   to	   achieve	   the	   agreed	   goals.	   For	   example,	  
partners	   are	   extending	   programs	   to	   provide	   drugs,	   thus	   covering	   requirements	   up	   to	  
2020.	  They	  are	  also	  providing	  research	  knowledge,	  molecules	  and	  funds	  to	  develop	  new	  
drugs	  and	  a	  system	  for	  distributing	  drugs	  faster.	  In	  the	  London	  Declaration	  on	  Neglected	  
Tropical	   Diseases,	   the	   participants	   furthermore	   undertake	   to	   cooperate	   more	   closely	  
and	  to	  document	  progress.	  
	  
In	   the	   course	   of	   the	   initiative,	   Bayer	   is	   particularly	   active	   in	   projects	   fighting	   Chagas	  
disease	   and	   African	   sleeping	   sickness.	   It	   is	   also	   making	   molecules	   available	   from	   its	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Chapter	  5	  -­‐	  Conclusion,	  Limitations	  and	  Future	  Research	  
Conclusion	  
This	   thesis	   main	   research	   question	   was	   to	   try	   to	   understand	   how	   has	   the	   tension	  
between	   the	   accessibility	   of	   essential	   medication	   in	   developing	   countries	   and	  
intellectual	   property	   rights	   influenced	   the	   CSR	   strategy	   of	  multinational	   companies	   in	  
the	   pharmaceutical	   industry	   over	   the	   last	   years.	   The	   topic	   of	   CSR	   is	   among	   the	  most	  
hotly	  debated	  globalization	  topics	  and,	  according	  to	  Carroll	  (1979),	  it	  is	  possible	  to	  say	  
that	   the	   social	   responsibility	   of	   businesses	   embraces	   the	   economic,	   legal,	   ethical	   and	  
discretionary	   expectations	   that	   society	   has	   of	   organizations	   at	   a	   certain	  point	   of	   time.	  
Increased	  attention	   to	  CSR	  by	  corporations	  has	  not	  been	   fully	  voluntary,	  as	   significant	  
number	  of	  companies	  only	  realized	  its	  importance	  when	  surprised	  by	  public	  responses	  
to	  issues	  they	  had	  not	  previously	  considered	  part	  of	  their	  business	  responsibilities,	  such	  
as	  GSK.	  
	  
From	   the	   research	  developed	   it	   is	   possible	   to	   conclude	   that	   the	  moment	   relevant	   and	  
emerging	  stakeholders,	  such	  as	  customers	  and	  NGOs,	  became	  involved	  in	  the	  access	  to	  
medicines	  conflict,	  and	  reputational	  damage	  became	  a	  potential	  reality,	  ensured	  that	  a	  
start	  was	  made	  in	  meeting	  the	  needs	  of	  HIV	  and	  AIDS	  victims	  in	  the	  developing	  world	  by	  
the	   company.	   GSK,	   that	   at	   the	   beginning	   adopted	   a	   reactive	   and	   defensive	   approach	  
(“don’t	   do	   things	   wrong”),	   had	   to	   discipline	   itself	   during	   the	   course	   of	   the	   conflict,	  
integrating	   inside-­‐out	  and	  outside-­‐in	  practices.	  The	  company	  changed	   its	   strategy	   to	  a	  
proactive/interactive	   approach	   to	  CSR,	   consisting	  on	   “doing	   the	   right	   things	   right”.	  As	  
so,	  it	  is	  possible	  to	  conclude	  that	  GSK’s	  approaches	  to	  CSR	  came	  from	  a	  desire	  to	  do	  good	  
and	   an	   enlightened	   self-­‐interest,	   and	   that	   the	   interest	   of	   the	   stakeholders	   has	   been	  
acceded	  to	  most,	  looking	  at	  the	  GSK	  initiatives	  and	  price	  cuts.	  
	  
Effective	  CSR	   is	  normally	  a	   long-­‐term	  position,	  as	   it	   is	  an	   investment	   in	   the	  company’s	  
future,	  requiring	  planning,	  supervision	  and	  evaluation	  on	  a	  regular	  basis.	  According	  to	  
Porter	  &	  Kramer	  (2006),	  corporations	  have	  to	  incorporate	  a	  social	  perspective	  into	  the	  
core	  model	  that	  is	  exercised	  to	  comprehend	  competition	  and	  guide	  its	  business	  strategy,	  
and	   that	   was	   precisely	   what	   GSK	   did.	   By	   suggesting	   that	   GSK’s	   priority	   was	   public	  
health,	   the	   company	   identified	   the	  points	  of	   intersection	  between	  society	  and	   the	  
corporation	   and	   demonstrated	   a	   clear	   choice	   of	   the	   social	   issues	   to	   address.	  GSK	  
has	  incorporated	  a	  social	  dimension	  to	  its	  value	  proposition	  since	  the	  beginning	  of	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its	   existence,	   making	   social	   impact	   part	   of	   the	   overall	   strategy:	   “We	   are	   dedicated	   to	  
improving	  the	  quality	  of	  human	  life	  by	  enabling	  people	  to	  do	  more,	  feel	  better	  and	  live	  
longer”.	   In	  addition,	  and	  as	  previously	  mentioned,	  the	  company	  started	  to	  engage	  in	  a	  
in/outside-­in/out	  business	  orientation,	  establishing	  a	  dialogue	  with	  stakeholders	  and	  
promoting	   partnerships.	   GSK	   also	   created	   a	   corporate	   social	   agenda,	   to	   create	  
opportunities	   to	   reach	   social	   and	   economic	   benefits	   at	   the	   same	   time,	  which	   focus	   on	  
strategic	   CSR.	   It	   is	   through	   it	   that	   the	   most	   significant	   social	   impact	   and	   business	  
benefits	   are	   achieved.	   A	   good	   illustration	   of	   this	   is	   the	   access	   strategy	   Facing	   the	  
Challenge:	  Our	  Contribution	  to	   Improving	  Healthcare	   in	   the	  Developing	  World,	   launched	  
in	  2001,	  which	  considered	  clear	  and	  measurable	  goals	  and	  tracks	  results	  over	  time.	  	  
	  
To	   conclude,	   the	   commotion	   surrounding	   the	   price	   of	   HIV/AIDS	   medicines	   persists.	  
Disputes	   such	  as	   the	  South	  African	  Trade	  Dispute	  have	  kept	  arising	  and	   this	  has	  been	  
viewed	  as	  a	  CSR	  issue	  –	  through	  patent	  policy,	  pharmaceutical	  companies	  are	  restricting	  
access	  of	  ARV	  drugs	  to	  those	  most	  in	  need.	  A	  resolution	  to	  the	  issue	  is	  still	  forthcoming,	  
and	  GSK	   indicates	   constantly	   that	   the	   company	   does	   not	   see	   itself	   able	   to	   resolve	   the	  
problem	   surrounding	   prices	   on	   its	   own.	   The	   company	   recognizes	   that	   access	   to	  
medicines	   is	   a	   complex	   and	   multi-­‐faceted	   issue	   with	   no	   simple	   answer,	   where	   the	  
challenges	   can	   only	   be	   properly	   addressed	   through	   partnerships	   between	   developed	  
and	   developing	   country	   governments,	   international	   organizations,	   the	   industry	   and	  
charitable	   organizations.	   	   While	   the	   conflict	   drags	   on,	   the	   acuteness	   of	   the	   clash	   has	  
diminished	  somewhat	  thanks	  to	  the	  initiatives	  GSK	  has	  launched.	  	  
Limitations	  and	  Future	  Research	  
By	   combining	   the	   findings	   from	   the	   literature	   review	   and	   the	   case	   study,	   conclusions	  
have	   been	   reached.	   However,	   the	   research	   conducted	   within	   this	   thesis	   is	   bound	   to	  
several	   limitations.	   First	   of	   all,	   the	  most	   straightforward	   limitation	   is	   related	  with	   the	  
fact	   that	   the	  methodology	   adopted	  was	   a	   case	   study,	   namely	   relying	   on	   one	   company	  
only,	  and	  therefore,	  the	  context	  data	  and	  its	  availability	  are	  extremely	  conditioned	  to	  the	  
company	  chosen	  –	  it	  might	  not	  be	  representative	  for	  the	  industry	  as	  a	  whole.	  However,	  
the	  findings	  could	  hold	  for	  other	  pharmaceutical	  companies	  as	  well,	  and	  are	  a	  valuable	  
resource	  for	  future	  researchers	  who	  may	  be	  interested	  in	  studying	  the	  company,	  mainly	  
if	  one	  intends	  to	  focus	  on	  its	  CSR	  practices.	  In	  addition,	  the	  information	  gathered	  during	  
research,	   upon	   which	   the	   dissertation	   was	   built,	   consisted	   mainly	   of	   secondary	   data,	  
publicly	  available,	  and	  information	  provided	  by	  GSK.	  Primary	  data	  was	  only	  collected	  in	  
the	  form	  of	  interviews	  to	  the	  company.	  The	  lack	  of	  other	  data	  collection	  sources,	  namely	  
quantity	   research	   methods,	   as	   in	   the	   form	   of	   surveys	   or	   focus	   group,	   constitutes	   a	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limitation	  to	  this	  dissertation.	   	  Limitations	  on	  the	  availability	  of	  exact	  figures	  from	  GSK	  
on	   their	   sales	   per	   country	   limited	   the	   conclusions	   drawn	   from	   the	   findings,	   as	   some	  
countries	  are	  grouped	  in	  regions,	  like	  the	  rest	  of	  the	  world/international	  region,	  where	  
the	   least	  developed	  countries	   fit.	  Furthermore,	   in	  order	  to	  assess	  the	   impact	  of	   IPR	  vs.	  
access	   to	  medicines	   issue	   on	   the	   reputation	   of	   the	   firm	  and	   consequently	   its	   strategy,	  
sales	   figures	   and	   the	   capital	   market	   have	   been	   used	   as	   a	   mean	   to	   analyze	   the	  
relationship.	   Though,	   an	   abundance	  of	   other	   factors	   such	   as	   pricing	   strategies,	  
competition,	  patent	  lengths,	   legislation	  on	  healthcare	  and	  insurances	  have	  a	  significant	  
impact	  on	  these	  figures	  as	  well	  and	  limit	  therefore	  the	  findings.	  Lastly,	  some	  limitations	  
have	   to	   do	   with	   the	   research	   topic	   itself	   –	   CSR	   –	   as	   it	   is	   subject	   to	   different	  
interpretations	  and	  definitions,	  which	  leads	  to	  different	  perspectives	  that,	   in	  turn,	  hold	  
back	   further	  development	   in	   the	  area.	   In	   addition,	   there	  are	  not	   standardized	  ways	  of	  
measuring	  the	  impact	  of	  CSR	  policies,	  maybe	  due	  to	  its	  qualitative	  nature	  and	  the	  lack	  of	  
studies	  and	  standardized	  methodology.	  	  	  
	  
This	  study	  gave	  insights	  on	  the	  topic	  of	  the	  effect	  of	  IPR	  vs.	  access	  to	  medicines	  on	  firm	  
strategies.	   Future	   research	   on	   the	   topic	   of	   IPR	   and	   promoting	   access	   to	   medicines	  
should	  adopt	  an	  industry	  wide	  perspective	  and	  statements	  made	  by	  companies	  should	  
be	  investigated	  more	  thoroughly.	  Within	  this	  research	  a	  company	  perspective	  has	  been	  
adopted.	  However,	  future	  research	  should	  as	  well	  adopt	  a	  perspective	  focused	  on	  either	  
the	  role	  of	  governments,	  civil	  society	  organizations,	  tripartite	  institutions,	  ethics	  or	  the	  
socio-­‐economic	   environment.	   Efforts	   in	   order	   to	   investigate	   a	   specific	   set	   of	   countries	  
more	   thoroughly	   should	  be	  pursued	  as	  well.	   Such	   research	  will	  provide	  more	   insights	  
into	   the	   relationship	   and	   effect	   of	   a	   country’s	   position	   on	   the	   topics	   of	   e.g.	   healthcare	  
insurance,	  specific	  pricing	  mechanisms,	  national	  healthcare	  systems,	  since	  these	  factors	  
have	  an	  impact	  on	  company	  strategies	  as	  well.	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Appendices	  
	  




Medicine-­related	  health	  targets	   Medicine-­related	  health	  	  
Indicators	  
Goal	   4:	   Reduce	   child	  
mortality	  
Target	   5:	   Reduce	   by	   two-­‐thirds,	  
between	   1990	   and	   2015,	   the	   under-­‐
five	  mortality	  rate	  
13.	  Under-­‐five	  mortality	  rate	  
14.	  Infant	  mortality	  rate	  
Goal	   5:	   Improve	  
maternal	  health	  
Target	   6:	   Reduce	   by	   three-­‐quarters,	  
between	  1990	  and	  2015,	   the	  maternal	  
mortality	  ratio	  
16.	  Maternal	  mortality	  ratio	  
Goal	   6:	   Combat	  
HIV/AIDS,	   malaria	   and	  
other	  diseases	  
Target	   7:	   Have	   halted	   by	   2015	   and	  
begun	   to	   reverse	   the	   spread	   of	  
HIV/AIDS	  
18.	   HIV	   prevalence	   among	   pregnant	   women	  
aged	  15-­‐24	  years	  
19.	   Condom	   use	   rate	   of	   the	   contraceptive	  
prevalence	  rate	  
	   Target	   8:	   Have	   halted	   by	   2015	   and	  
have	  begun	  to	  reverse	  the	  incidence	  of	  
malaria	  and	  other	  major	  diseases	  
21.	  Prevalence	  and	  death	  rates	  associated	  with	  
malaria	  
22.	   Proportion	   of	   population	   in	   malaria-­‐risk	  
areas	   using	   effective	   malaria	   prevention	   and	  
treatment	  measures	  
23.	  Prevalence	  and	  death	  rates	  associated	  with	  
tuberculosis	  
24.	   Proportion	   of	   tuberculosis	   cases	   detected	  
and	  cured	  under	  DOTS	  
Goal	   8:	   Develop	   a	  
global	   partnership	   for	  
development	  
Target	   12:	   Develop	   further	   an	   open,	  
rule-­‐based,	   predictable,	   non-­‐
discriminatory	   trading	   and	   financial	  
system	  
	  
	   Target	  13:	  Address	  the	  special	  needs	  of	  
the	  least	  developed	  countries	  
	  
	   Target	   17:	   In	   cooperation	   with	  
pharmaceutical	   companies,	   provide	  
access	   to	  affordable,	  essential	  drugs	   in	  
developing	  countries	  
46.	   Proportion	   of	   population	   with	   access	   to	  
affordable	   essential	   drugs	   on	   a	   sustainable	  
basis	  (as	  defined	  by	  WHO)	  
	  
Source:	  WHO	  2008	  –	  WHO	  Medicines	  Strategy	  2008-­2013	  	  
	  




















Be	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Annex	  3	  -­‐	  Median	  availability	  of	  selected	  generic	  medicines	  in	  public	  and	  private	  




















Note:	  The	  numbers	  above	  the	  group	  labels	  refer	  to	  the	  number	  of	  countries	  
Source:	  World	  Health	  Organization	  /	  Health	  Action	  International	  
	  
Annex	  4	  –	  Ratio	  of	  consumer	  prices	  to	  international	  reference	  prices	  for	  selected	  














Note:	  The	  numbers	  above	  the	  group	  labels	  refer	  to	  the	  number	  of	  countries	  
	  
Source:	  World	  Health	  Organization	  /	  Health	  Action	  International	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Annex	  5	  -­‐	  Access	  to	  Medicine	  Index	  Methodology	  Framework	  
	  
Source:	  Access	  to	  Medicine	  Index	  Report	  2012	  
	  
	  
Annex	  6-­‐	  Script	  for	  the	  interviews	  
	   	  
1.	   Pharmaceutical	   companies	   adopted	   a	   fresh	   thinking	   about	   the	   world’s	   neglected	  
diseases,	  which	  affect	  so	  many	  people.	  Still,	  it	  comes	  at	  an	  interesting	  time,	  as	  it	  is	  well	  
known	   from	   the	   business	   perspective	   that	   the	   pharmaceutical	   business	   model	   is	  
challenged.	  Drug	  pipelines	  at	  many	  large	  companies	  are	  not	  as	  productive	  as	  they	  were,	  
and	   there	   are	   also	   quite	   aggressive	   generic	   challengers.	   This	   creates	   a	   question	   about	  
the	  incentives	  for	  investing	  in	  future	  innovation,	  what	  might	  be	  the	  business	  model.	  Can	  
companies	  go	  beyond	  the	  blockbuster	  to	  a	  new	  kind	  of	  business	  model?	  	  
	  
2.	  GSK	   -­	   Your	   company	   has	   been	   rated	   number	   one	   on	   the	   access	   to	  medicine	   index	  
since	   2008,	   because	   of	   your	   efforts	   to	   expand	   access	   to	   medications	   in	   some	   less	  
developed	  areas	  of	   the	  world.	  How	  do	  you	  continue	   to	  expand	  access	   to	  medicines	  by	  
either	  discounting	  or	  donating	  them	  and,	  at	  the	  same	  time,	  maintain	  the	  profitability	  for	  
the	  company?	  
	  
Bayer	  -­‐	  Your	  company	  has	  been	  rated	  number	  nine	  on	  the	  access	  to	  medicine	  index	  in	  
2012,	  because	  of	  your	  efforts	   to	  expand	  access	   to	  medications	   in	   some	   less	  developed	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areas	   of	   the	   world.	   How	   do	   you	   continue	   to	   expand	   access	   to	   medicines	   by	   either	  
discounting	  or	  donating	   them	  and,	   at	   the	   same	   time,	  maintain	   the	  profitability	   for	   the	  
company?	  
	  	  
3.	   Corporate	   Social	   Responsibility	   has	   never	   been	   more	   prominent	   on	   the	   corporate	  
agenda.	   The	   debate	   about	   CSR	   has	   shifted:	   it	   is	   no	   longer	   about	   whether	   to	   make	  
substantial	   commitments	   to	  CSR,	   but	   how.	  The	   challenge	   is	   developing	  CSR	   initiatives	  
consistent	  with	  a	  strategic	  purpose.	  Would	  you	  agree	  with	  this?	  
How	  has	   your	   CSR	   strategy	   changed	   because	   of	   this	   fact	   and	   how	  has	   your	   corporate	  
agenda	  been	  affected	  by	  CSR?	  	  
	  
4.	   Is	   stakeholder	   engagement	   at	   the	   core,	   when	   figuring	   out	   a	   CSR	   strategy	   for	   your	  
company?	  
	  
5.	  At	  the	  same	  time	  of	  the	  commercial	  constraints	  described	  in	  question	  1,	  we	  are	  also	  
living	  at	  a	  time	  of	  tremendous	  challenges	  in	  global	  health.	  Not	  only	  HIV,	  TB	  and	  malaria,	  
but	   also	   neglected	   diseases.	   The	   private	   sector	   is	   increasingly	   called	   upon	   to	   address	  
social	   problems,	   also	   due	   to	   the	   growing	   recognition	   of	   the	   failure	   of	   governments	   to	  
solve	  them.	  What	  is	  the	  capacity	  and	  responsibility	  of	  a	  global	  pharmaceutical	  company	  
to	  help	  be	  a	  good	  corporate	  citizen	  when	  thinking	  about	  global	  health	   issues,	  and	  how	  
much	  is	  enough?	  	  
Do	  you	  measure	  your	  social	  performance?	  If	  so,	  how?	  
	  
6.	   Pharmaceutical	   companies	   are	   well	   known	   for	   their	   philanthropic	   activities,	   which	  
include	   giving	   away	   large	   quantities	   of	   their	   products.	   Still,	   this	   did	   not	   prevent	   the	  
industry’s	   vilification	   over	   its	   response	   to	   the	   HIV/AIDs	   crisis	   in	   South	   Africa,	   for	  
example.	  Accused	  of	  putting	  profits	  before	  people,	   the	  pharmaceutical	   industry	  stated,	  
“The	  case	   is	  nothing	  to	  do	  with	  blocking	  access	  to	  medicines,	  or	  price	   fixing.	   It’s	  about	  
patents.	  Patents	  do	  not	  block	  medicines.	  They	  stimulate	  research	  and	  development”.	  Can	  
you	  comment	  the	  relation	  between	  access	  to	  medicines	  and	  patents?	  
	  
7.	  In	  the	  Health	  sector,	  it	  has	  been	  realized	  that	  the	  problems	  most	  difficult	  to	  manage,	  
such	  as	  the	  access	  to	  medicines	  issue,	  need	  new	  ways	  of	  working	  together,	  in	  addition	  to	  
better	   coordination	   of	   traditional	   roles,	   to	   reach	   a	   combination	   of	   the	   strengths,	  
resources	  and	  expertise	  of	   the	  different	   sectors	   (public	   sector,	  private	   sector	  and	  civil	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society).	  Do	  you	  believe	  partnerships	  are	  the	  solution,	  if	  there	  is	  a	  solution	  at	  all?	  What	  
is	  for	  you	  the	  best	  way	  to	  try	  to	  overcome	  this	  issue?	  
	  
Annex	  7.	  Bayer	  Health	  Care	  answers	  to	  the	  interview	  
	  
1.	   Bayer	   HealthCare	   Pharmaceuticals	   has	   set	   itself	   an	   ambitious	   goal:	   we	   want	   to	  
improve	  people's	  health	  and	  quality	  of	  life	  with	  innovative	  therapies.	  This	  is	  the	  basis	  of	  
our	  current	  and	  future	  economic	  success.	  Our	  innovative	  medicines	  meet	  global	  medical	  
needs	   focusing	   on	   diseases	   which	   carry	   a	   high	   burden	   for	   patients	   and	   healthcare	  
systems.	  However,	  economic	  strength	  also	  means	  a	  great	  responsibility.	  We	  would	  like	  
all	  people	  to	  share	  the	  fruits	  of	  medical	  progress,	  regardless	  of	  their	  origins	  or	  income.	  
We	  support	  programs	   that	  provide	  access	   to	   innovative	  medicines	  and	  modern	   family	  
planning,	   and	   take	  up	   the	   fight	   against	  neglected	  diseases.	  We	  work	   side-­‐by-­‐side	  with	  
aid	  agencies,	  international	  bodies	  and	  policy	  makers.	  	  
	  
2.	   All	   over	   the	   world,	   patients	   need	   access	   to	   quality	   drugs	   and	   health	   services.	   Aid	  
organizations	   use	   donations	   to	   supply	   drugs	   free	   of	   charge	   to	   people	   who	   otherwise	  
cannot	   afford	   them.	   Many	   people	   worldwide	   are	   without	   adequate	   access	   to	   medical	  
care	  –	  and	  not	  only	   in	  very	  poor	  countries.	  Emerging	  industrial	  nations	   like	  China	  face	  
the	  task	  of	  building	  up	  a	  nationwide	  health	  system,	  while	  simultaneously	  having	  to	  deal	  
with	   a	   sharp	   increase	   in	   typical	   lifestyle	   diseases,	   as	   e.g.	   diabetes	   and	   cardiovascular	  
diseases.	   In	  areas	  where	  government	  agencies	  cannot	  guarantee	  medical	  care,	  patients	  
have	   to	  pay	   for	  expensive	   treatments	  drugs	   themselves.	  By	  offering	  Patient	  Assistance	  
Programs,	  Bayer	  HealthCare,	  together	  with	  partners	  from	  local	  healthcare	  systems	  and	  
NGOs,	  is	  helping	  to	  close	  such	  healthcare	  gaps.	  However,	  many	  poor	  countries	  also	  have	  
a	  working	  middle	  class	  who	  would	  like	  to	  –	  and	  can	  –	  afford	  to	  buy	  medicines	  at	  a	  price	  
that	   is	   affordable	   for	   them.	   In	   addition	   to	   donations	   and	   emergency	   aid	   we	   apply	   in	  
developing	  countries	  various	  mechanisms	  like	  price	  differentiation	  by	  purchase	  power	  
and	  affordability,	  according	  to	  market	  conditions,	  and	  other	  mechanisms	  as	  e.g.	  second-­‐
tier	   pricing.	   	   In	   collaboration	  with	   government	   agencies	   and	   NGOs,	   we	   run	   programs	  
that	  supply	  the	  population	  groups	  affected	  in	  an	  economically	  viable	  way,	  thus	  ensuring	  
that	  the	  programs	  remain	  sustainable.	  
	  
Let	  me	  give	  you	  an	  example:	  the	  Contraceptive	  Security	  Initiative	  (CSI),	  the	  first	  project	  
of	  its	  kind	  in	  sub-­‐Saharan	  Africa,	  which	  has	  been	  launched	  by	  Bayer	  Healthcare	  and	  the	  
U.S.	   Development	   Agency	   USAID.	   CSI	   helps	   to	   be	   able	   to	   guarantee	   the	   consistent	  
availability	   of	   contraceptives	   in	   developing	  markets.	   It’s	   an	   alternative	   to	   subsidizing	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access	   to	   oral	   contraceptives,	   and	   one	   that	   is	   economically	   sustainable	   and	   therefore	  
more	   reliable	   in	   the	   long	   run	   than	   subsidies.	  We	   have	   adjusted	   the	   price	   for	   an	   oral	  
contraceptive	   to	   the	   financial	   resources	   of	   middle-­‐income	   women.	   This	   offers	   an	  
additional	   option	   to	   self-­‐determined	   family	   planning	   which	   makes	   modern	   oral	  
contraception	   affordable	   at	   the	   same	   time	   covers	   costs	   and	   supply	   chain	   margins	   -­‐	  
independently	  from	  obtaining	  free	  or	  subsidized	  contraceptives	  from	  aid	  organizations.	  
Since	   wholesalers	   and	   pharmacy	   owners	   are	   involved	   in	   the	   supply	   chain,	   it	   creates	  
income	  for	  the	  national	  economy	  that	  offers	  a	  way	  out	  of	  purely	  charitable	  support	  and	  
contributes	   to	   sustainable	   development.	   For	  women	   this	   has	   an	   additional	   advantage:	  
they	   not	   only	   avoid	   long	  waiting	   times	   in	   public	   hospitals’	   dispensaries,	   but	   also	   they	  
steer	  clear	  of	  availability	  bottlenecks	  that	  may	  occur	  when	  products	  are	  distributed	  free.	  
The	   contraceptive	   pill	   will	   be	   introduced	   in	   eleven	   sub-­‐Saharan	   countries	   within	   the	  
next	   five	   years	   under	   the	   agreement	   between	   Bayer	   and	   USAID.	   Since	   2009,	   it	   has	  
already	  been	  successfully	   launched	   in	  Ethiopia,	  Uganda,	  Tanzania,	  Rwanda	  and	  Ghana.	  
USAID	   is	   funding	   the	   communication	   and	   educational	   measures	   supporting	   the	  
introductory	   phase	   of	   each	   country’s	   program.	   The	   aim	   over	   the	   initial	   five	   year	  
collaboration	   is	   to	   reach	   the	   necessary	   brand	   presence	   in	   project	   countries,	   and	   to	  
ensure	   that	   local	   women	   can	   rely	   on	   the	   product	   being	   consistently	   available	   in	   the	  
pharmacies.	  In	  return,	  Bayer	  guarantees	  that	  it	  will	  continue	  offering	  the	  product	  at	  the	  
agreed	  price	  beyond	  the	  formal	  end	  of	  the	  project’s	  contract	  period.	  
	  
Another	  example	  is	  our	  Jadelle	  Access	  Program:	  in	  2012	  an	  initiative	  involving	  a	  number	  
of	  organizations	  –	  including	  the	  Clinton	  Health	  Access	  Initiative,	  the	  Norwegian,	  British,	  
Swedish	   and	   US	   governments,	   the	   Children's	   Investment	   Fund	   Foundation	   and	   Bayer	  
HealthCare	   –	   announced	   at	   the	   UN	   Headquarters	   in	   New	   York	   their	   commitment	   to	  
make	   a	   long	   acting	   and	   reversible	   contraceptive	   method	   available	   to	   more	   than	   27	  
million	  women	  in	  the	  poorest	  countries	  of	  the	  world.	  The	  initiative	  focuses	  on	  Jadelle,	  an	  
implant	  providing	  long-­‐acting	  reversible	  contraception	  for	  up	  to	  five	  years	  and	  has	  been	  
prequalified	   by	   the	  WHO.	   The	   commitment	   announced	   at	   the	   United	   Nations	   in	   New	  
York	  was	  enshrined	   in	  a	   contract.	  The	   contracting	  parties	  –	  Bayer	  HealthCare	  and	   the	  
Bill	  &	  Melinda	  Gates	  Foundation	  –	  agreed	  to	  supply	  the	  Bayer	  contraceptive	  implant	  to	  
at	   least	  27	  million	  women	   in	  developing	  countries	   for	  a	  period	  of	  six	  years	   from	  2013	  
on.	   Bayer	   had	   reduced	   the	   price	   of	   Jadelle	   and	   in	   turn,	   the	   Bill	   &	   Melinda	   Gates	  
Foundation	  covered	  the	  risk	  of	  default.	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Furthermore,	  Bayer	  Healthcare	  has	   a	   long-­‐standing	   cooperation	  with	  WHO	   in	   fighting	  
Neglected	  Tropical	  Disease.	  Since	  more	  than	  a	  decade	  Bayer	  supports	  WHO	  in	   fighting	  
Chagas	   disease	   in	   Latin	   America	   as	   well	   as	   African	   sleeping	   sickness	   by	   donation	  
essential	  medicines	  to	  treat	  these	  patients.	  Since	  sometimes	  more	  than	  just	  medication	  
is	  needed,	  Bayer	  provides	  also	  financial	  support	  for	  distribution	  of	  these	  medicines.	  Just	  
a	   few	  weeks	   ago	   in	   2013	  we	   signed	   another	   agreement	  with	  WHO	   to	   support	  mobile	  
intervention	  teams	  on	  the	  ground	  in	  the	  DR	  Congo	  to	  identify	  and	  control	  local	  disease	  
areas	  with	  outbreaks	  of	  African	  sleeping	  sickness.	  This	  way	  Bayer	  HealthCare	  supports	  
the	  goals	  set	  in	  the	  London	  Declaration	  on	  NTDs	  to	  eliminate	  African	  sleeping	  sickness	  
and	  control	  Chagas	  disease	  by	  2020.	  
	  
3.	  Bayer	  was	  one	  of	  fifty	  companies	  worldwide	  that	  established	  the	  UN	  Global	  Compact	  
in	  the	  year	  2000.	  UN	  General	  Secretary	  Kofi	  Annan	  inaugurated	  the	   initiative	  with	  this	  
statement:	  “Let	  us	  choose	  to	  unite	  the	  power	  of	  markets	  with	  the	  strength	  of	  universal	  
ideals.”	  On	  a	  global	  level	  it	  has	  four	  overriding	  objectives:	  	  
•	  to	  promote	  human	  rights	  
•	  to	  guarantee	  international	  labor	  standards	  
•	  to	  improve	  environmental	  protection	  and	  
•	  to	  fight	  corruption.	  	  
Bayer's	  corporate	  social	  responsibility	  has	  traditionally	  involved	  assistance	  for	  those	  in	  
need	  and	  efforts	  to	  improve	  social	  conditions	  in	  all	  the	  countries	  in	  which	  the	  company	  
is	  active.	  Important	  tools	  of	  our	  social	  responsibility	  include	  donations	  and	  support	  for	  
long-­‐term	  projects	  according	  to	  the	  principle	  "helping	  people	  to	  help	  themselves."	  Here	  
we	   cooperate	   closely	   with	   both	   government	   institutions	   and	   non-­‐governmental	  
organizations.	  	  
	  
In	   2009	   Bayer	   developed	   a	   Sustainability	   Program.	   The	   program	   places	   special	  
importance	  on	  alliances	  for	  sustainable	  health	  care,	  innovative	  partnerships	  to	  improve	  
the	  supply	  of	  high-­‐quality	   food.	  Bayer	   is	   facing	  up	  to	   this	  challenge	   in	  keeping	  with	   its	  
mission	   “Bayer:	   Science	  For	  A	  Better	   Life.”	   Sustainability	   is	   also	   key	   to	   all	   our	  Patient	  
Assistance	   Programs	   and	   reflects	   our	   long-­‐term	   commitment	   to	   provide	   access	   to	  
medicines	  to	  those	  who	  need	  them.	  
	  
Thanks	   to	   our	   strategic	   commitment,	   the	   services	   of	   our	   HealthCare	   business	   –	   high-­‐
quality	  drug	  products	  and	  treatments	  –	  are	  being	  made	  available	  to	  patients	  across	  the	  
globe	  in	  countless	  programs.	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4.	  Stakeholder	  engagement	  is	  at	  the	  core	  of	  our	  CSR	  and	  “Access	  to	  Medicines”	  strategy.	  
Since	  long	  we	  engage	  and	  network	  with	  various	  national	  and	  international	  organization,	  
institutions,	  NGOs	  and	  government	  authorities.	  We	  see	  us	  as	  private	  industry	  as	  partner	  
in	   finding	   solutions	   for	   better	   healthcare.	   Our	   cooperation	  with	   USAID	   and	   the	   Bill	   &	  
Melinda	   Gates	   Foundation	   in	   our	   core	   competence	   area	   of	   contraception	   and	   Family	  
Planning	   may	   be	   a	   good	   example	   to	   illustrate	   this.	   Since	   more	   than	   10	   years	   we	  
established	  the	  “international	  Dialogue	  on	  Population	  and	  Sustainability”	  as	  platform	  for	  
interaction	  and	  discussion	  with	  stakeholders	  active	  in	  this	  area.	  
	  
Since	   2009,	   on	   a	   biannual	   basis,	   the	   ATM	   Index	   rates	   the	   top-­‐20	   pharmaceutical	  
companies	   regarding	   their	   performance	   in	   increasing	   access	   to	  medicines.	   In	   the	   last	  
2012	   rating	   Bayer	   ranked	   #9	   among	   the	   leading	   pharmaceutical	   companies,	   which	  
reflects	  the	  acceptance	  of	  our	  engagement	  in	  this	  area.	   	  
	  
5.	  As	  a	  company,	  we	  are	  firmly	  rooted	  in	  society	  –	  as	  a	  reliable	  employer	  and	  trainer,	  as	  
a	   good	   neighbor	   at	   our	   locations	   all	   over	   the	  world,	   as	   an	   organization	   that	   uses	   and	  
protects	  natural	   resources.	   It	   comes	  natural	   to	  us	   to	  deal	  with	  people	   and	  nature	   in	   a	  
respectful	  and	  sustainable	  manner,	  to	  act	  unconditionally	  in	  accordance	  with	  applicable	  
laws,	  and	  to	  maintain	  the	  highest	  standards.	  
	  
We	  believe	   responsibility	   lays	   the	   foundation	   for	   long-­‐term	   confidence	   in	   the	   reliable,	  
high	   quality	   of	   our	   work	   and	   products.	   There	   must	   be	   a	   healthy	   balance	   between	  
economy,	  ecology	  and	  society	  –	  and	  this	  conviction	  is	  the	  basis	  of	  our	  actions.	  
	  
Our	  performance	  regarding	  social	  engagement	  and	  contribution	  to	  society	  are	  published	  
in	  the	  annual	  Bayer	  Sustainability	  Report.	  As	  pharmaceutical	  company	  our	  contribution	  
to	  healthcare	  and	  access	  to	  medicines	  are	  core	  of	  activities.	  
	  
6.	   Our	   outstanding	   capacity	   for	   innovation	   is	   based	   on	   several	   factors.	   This	   demands	  
consistently	  high	  investments	  in	  research	  and	  development.	  In	  the	  last	  five	  years,	  Bayer	  
has	  always	  maintained	  a	  research	  budget	  of	  around	  €3	  billion,	  regardless	  of	  economic	  
developments.	   It	   is	   also	   important	   to	   have	   a	   policy	   of	   sound	   innovation	  management	  
with	  clear	  structures,	   focus	  and	  discipline	  coupled	  with	  a	  corporate	  culture	   that	  offers	  
researchers	   a	   suitable	   working	   environment	   and	   reinforces	   the	   importance	   of	  
innovation	   –	   and	   therefore	   researchers	   –	   for	   our	   company.	   We	   also	   measure	   our	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sustainable	  innovative	  strength	  through	  additional	  KPIs,	  such	  as	  the	  number	  of	  patents	  
registered	  each	  year	  and	  the	  quality	  of	  these	  patents.	  	  
	  
Reliable,	   global	  protection	  of	   intellectual	  property	   rights	   is	   essential	   for	  an	   innovation	  
company	  like	  Bayer.	  Protected	  products	  or	  processes	  currently	  account	  for	  an	  estimated	  
40	   percent	   of	   Bayer’s	   sales.	   At	   the	   end	   of	   2012	   we	   held	   approximately	   76,000	   valid	  
patent	   registrations	   and	   patents,	   and	   a	   further	   roughly	   10,000	   protected	   inventions.	  
Bayer	   undertakes	   approximately	   6,500	   patent	   registrations	   worldwide	   each	   year.	   A	  
patent	  generally	  remains	  valid	  for	  20	  years.	  As	  it	  takes	  12	  years	  on	  average	  to	  develop	  a	  
new	   pharmaceutical,	   only	   eight	   years	   of	   patent	   protection	   generally	   remain	   following	  
the	  product’s	  approval.	  Without	  such	  protection,	   it	  would	  not	  be	  possible	   to	  cover	   the	  
significant	   costs	   incurred	   in	   the	   research	   and	   development	   of	   innovative	  
pharmaceuticals	   and	   to	   plan	   new	   therapeutic	   options.	   We	   therefore	   advocate	   the	  
protection	   of	   both	   the	   international	   patent	   system	   and	   our	   own	   intellectual	   property	  
worldwide.	  	  
	  
7.	  The	  challenge	  of	  answering	  pressing	  healthcare	  issues	  worldwide	  is	  a	  huge	  task	  that	  
no	   aid	   organization,	   government,	   company	   or	   research	   institute	   can	   manage	   alone.	  
However,	  as	  part	  of	  a	  network	  of	  strong	  partners	  it	  is	  possible	  to	  make	  a	  real	  difference.	  
We	   initiate	   and	   support	   many	   cooperation	   projects	   that	   are	   committed	   to	   improving	  
healthcare	  –	  be	  it	  in	  family	  planning,	  the	  fight	  against	  neglected	  and	  infectious	  diseases,	  
training	  medical	  personnel,	  sex-­‐education	  campaigns,	  or	  programs	  to	  give	  people	  with	  
low	  incomes	  access	  to	  the	  drugs	  they	  need.	  In	  addition	  to	  donating	  medicines	  or	  money	  
to	   overcome	   acute	   emergencies,	   our	   engagement	   concentrates	   mainly	   on	   sustainable	  
concepts	  for	  long-­‐term	  improvements	  in	  healthcare.	  
	  
Our	   partners	   include	   governmental	   and	   non-­‐governmental	   organizations	   with	  
longstanding	   experience	   in	   their	   respective	   fields,	   global	   networks	   and	   local	   contacts.	  
For	   example,	   for	   over	   50	   years,	   Bayer	  HealthCare,	   in	   collaboration	  with	   partners,	   has	  
been	  committed	  to	  giving	  women	  in	  developing	  countries	  the	  chance	  of	  self-­‐determined	  
family	  planning	  using	  quality	  hormonal	  contraceptives.	  
	  
Another	  area	  in	  which	  we	  cooperate	  closely	  with	  various	  partners	  is	  in	  the	  fight	  against	  
neglected	   tropical	   diseases	   (NTDs),	   which	   threaten	   1.4	   billion	   people	   worldwide;	   the	  
poorest	  of	  the	  poor	  in	  developing	  and	  transition	  countries	  are	  particularly	  at	  risk.	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As	  in	  the	  case	  of	  Neglected	  and	  Tropical	  Diseases,	  the	  fight	  to	  defeat	  these	  diseases	  and	  
improve	  people's	   living	   conditions	  particularly	   in	  poor	   endemic	   countries	   can	  only	  be	  
won	  as	  part	  of	  a	  concerted,	  major	  international	  effort.	  In	  2012,	  thirteen	  pharmaceutical	  
companies,	  the	  governments	  of	  the	  United	  States,	  the	  UK,	  and	  the	  United	  Arab	  Emirates,	  
the	   Bill	   &	   Melinda	   Gates	   Foundation,	   the	   World	   Bank	   and	   other	   global	   health	  
organizations	   launched	   the	  biggest	  campaign	   to	  date	   in	   the	   fight	  against	   the	  neglected	  
tropical	   diseases.	   The	   aim:	   to	   control	   or	   eradicate	   ten	   neglected	   tropical	   diseases	   in	  
collaboration	  with	  the	  countries	  affected	  by	  2020.	  
	  
The	  strength	  of	  the	  initiative	  is	  that	  renowned	  partners	  with	  global	  influence	  are	  using	  
their	  respective	  expertise	  and	  organizational	  skills	   in	  a	  concerted	  action	  to	  achieve	  the	  
agreed	   goals.	   For	   example,	   partners	   are	   extending	   programs	   to	   provide	   drugs,	   thus	  
covering	   requirements	   up	   to	   2020.	   They	   are	   also	   providing	   research	   knowledge,	  
molecules	  and	  funds	  to	  develop	  new	  drugs	  and	  a	  system	  for	  distributing	  drugs	  faster.	  In	  
the	   London	   Declaration	   on	   Neglected	   Tropical	   Diseases,	   the	   participants	   furthermore	  
undertake	  to	  cooperate	  more	  closely	  and	  to	  document	  progress.	  
	  
In	   the	   course	   of	   the	   initiative,	   we	   are	   particularly	   active	   in	   projects	   fighting	   Chagas	  
disease	  and	  African	  sleeping	  sickness.	  We	  are	  also	  making	  molecules	  available	  from	  our	  
library	  of	  compounds	  for	  research	  and	  the	  development	  of	  new	  therapies.	  
	  
